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ABSTRACT: The International Liaison Committee on Resuscitation 
has initiated a continuous review of new, peer-reviewed, published 
cardiopulmonary resuscitation science. This is the third annual summary 
of the International Liaison Committee on Resuscitation International 
Consensus on Cardiopulmonary Resuscitation and Emergency 
Cardiovascular Care Science With Treatment Recommendations. It 
addresses the most recent published resuscitation evidence reviewed 
by International Liaison Committee on Resuscitation Task Force science 
experts. This summary addresses the role of cardiac arrest centers 
and dispatcher-assisted cardiopulmonary resuscitation, the role of 
extracorporeal cardiopulmonary resuscitation in adults and children, 
vasopressors in adults, advanced airway interventions in adults and 
children, targeted temperature management in children after cardiac 
arrest, initial oxygen concentration during resuscitation of newborns, 
and interventions for presyncope by first aid providers. Members from 
6 International Liaison Committee on Resuscitation task forces have 
assessed, discussed, and debated the certainty of the evidence on the 
basis of the Grading of Recommendations, Assessment, Development, 
and Evaluation criteria, and their statements include consensus treatment 
recommendations. Insights into the deliberations of the task forces 
are provided in the Justification and Evidence to Decision Framework 
Highlights sections. The task forces also listed priority knowledge gaps for 
further research.
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This is the third in a series of annual International Liaison Committee on Resuscitation (ILCOR) Inter-national Consensus on Cardiopulmonary Resusci-
tation and Emergency Cardiovascular Care Science With 
Treatment Recommendations (CoSTR) summary publi-
cations that summarize the ILCOR task force analyses of 
published resuscitation evidence. The review this year 
addresses 12 topics by 6 task forces. Draft CoSTRs were 
posted online between November 12, 2018, and March 
20, 2019,1 and included the data reviewed and draft 
treatment recommendations, with comments accepted 
through April 4, 2019. The 12 draft CoSTR statements 
are now available online1 and have been viewed 23 654 
times since the first posting.
This summary statement contains the final wording 
of the CoSTR statements as approved by the ILCOR task 
forces and ILCOR member councils. This statement dif-
fers in several respects from the website draft CoSTRs: 
The language used to describe the evidence is not re-
stricted to standard Grading of Recommendations, As-
sessment, Development, and Evaluation (GRADE) termi-
nology,2 making it more transparent to a wider audience; 
the Justification and Evidence to Decision Framework 
Highlights sections have been expanded to provide more 
information about the rationale for treatment recom-
mendations; and finally, the task forces have prioritized 
knowledge gaps requiring future research studies.
The CoSTRs are based on task force analysis of the 
data, with the GRADE approach used to answer specif-
ic research questions. Each analysis has been detailed 
in a systematic review (SR), published by a Knowledge 
Synthesis Unit or systematic reviewer and the ILCOR topic 
experts.3–12 The GRADE approach rates the certainty of 
the evidence for an intervention and for each outcome as 
high, moderate, low, or very low. Data from randomized 
controlled trials (RCTs) are initially rated as high-certainty 
evidence; data from observational studies, as low-certainty 
evidence. Five factors may lead to downgrading of the 
certainty of evidence, and 3 factors may enable an up-
grade of the certainty of the evidence (Tables 1 and 2).
For each topic, the consensus on science generally 
includes the pertinent outcome data listing relative risk 
(RR) with 95% CI and risk difference with 95% CI or 
absolute risk difference (ARD) with 95% CI and patients 
with outcome per 1000 patients with 95% CI. For clar-
ity, much of this information is presented in tables. The 
consensus on science is followed by the treatment rec-
ommendation, the task force justification for the treat-
ment recommendation, and the important knowledge 
gaps identified by the task force.
The following topics are addressed in this CoSTR 
summary:
• Basic life support
– Dispatch instruction in adult cardiopulmonary 
resuscitation (CPR)
• Advanced life support (ALS) 
– Advanced airway interventions during adult car-
diac arrest
– Use of vasopressors in cardiac arrest
– Extracorporeal CPR (ECPR) for cardiac arrest in 
adults
• Pediatric life support
– Dispatcher-assisted CPR (DA-CPR) in pediatrics
– Advanced airway interventions in pediatric car-
diac arrest
– ECPR in infants and children
– Targeted temperature management (TTM) after 
cardiac arrest
• Neonatal life support (NLS)
– Initial oxygen concentration for term infants at 
birth
– Initial oxygen concentration for preterm infants 
at birth
• Education, Implementation, and Teams (EIT) and 
ALS
– Cardiac Arrest Centers (CACs) versus non-CACs
• First aid
– Presyncope
Readers are encouraged to monitor the ILCOR website1 
to provide feedback about planned SRs and to provide 
comments when additional draft reviews are posted.
BASIC LIFE SUPPORT
Dispatcher Instruction in CPR: DA-CPR—
Adults
The emergency medical dispatcher is an essential link 
in the chain of survival.13,14 In addition to dispatching 
emergency medical services (EMS) resources to medi-
cal emergencies, emergency medical dispatchers are 
increasingly being trained to recognize cardiac arrest, 
to assist bystanders in initiating resuscitation, and to 
support bystanders in optimizing resuscitation efforts. 
The international community is continuing to explore 
ways to increase bystander CPR for cardiac arrests. 
One such strategy involves dispatchers providing CPR 
instruction to callers/bystanders: DA-CPR. For such a 
strategy to be successful, it requires the EMS system 
to be configured to support the dispatcher to offer 
DA-CPR and the bystander to deliver CPR with support 
from the dispatcher.
ILCOR commissioned an SR to address the ef-
fect of DA-CPR on outcomes for patients in out-
of-hospital cardiac arrest (OHCA).3 A draft CoSTR 
was posted for public comment on the ILCOR web-
site15; the draft was viewed 1516 times during the 
public comment period. The task force reviewed the 
1 comment posted during this public commenting 
period.
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Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Adults with presumed cardiac arrest in out-
of-hospital settings
Intervention: Patients/cases or EMS systems where 
DA-CPR is offered 
Comparators: Studies with comparators where ei-
ther systems or specific cardiac arrest cases not offered 
DA-CPR are included
Outcomes: Critical: survival with favorable neuro-
logical function (at hospital discharge, 1 month, or 6 
months), survival (to hospital discharge, 1 month, or 
1 year), short-term survival (return of spontaneous cir-
culation [ROSC], hospital admission), and provision of 
bystander CPR. Important: initial shockable rhythm and 
time to CPR
Study designs: RCTs and nonrandomized stud-
ies (non-RCTs, interrupted time series, controlled 
before-and-after studies, cohort studies) eligible for 
inclusion
Time frame: All years and all languages included 
with the last search performed July 1, 2018; ongoing 
or unpublished studies identified through a search of 
ClinicalTrials.gov online registry16
PROSPERO registration: CRD42018091427
Note: The pediatric information is summarized else-
where in this document (see the Dispatcher Instruction 
in CPR: DA-CPR—Pediatrics section).
Consensus on Science
More than 5000 citations were reviewed, and 33 were 
identified as eligible for inclusion. These studies were 
classified into 2 categories: (1) systems, the compari-
son of outcomes when DA-CPR was offered versus not 
offered, and (2) bystander delivery, the comparison of 
outcomes for patients receiving DA-CPR versus those 
receiving no bystander CPR or unassisted bystander 
CPR. No randomized clinical trials were identified. 
Given that the only available data consisted of obser-
vational studies, we separately listed data when they 
came from an analysis adjusted for known confound-
ers because we felt that this provided a better esti-
mate of effect. The reliance on nonrandomized trials 
in the evidence review also means that the reported 
Table 1. GRADE Terminology for Strength of Recommendation and Criteria for Evidence Certainty Assessment
Strength of Recommendation
Strong Recommendation=We Recommend Weak Recommendation=We Suggest
Assessment Criteria for Certainty of Effect
Study Design
Certainty of Effect Begins at 
This Level Lower if Higher if
Randomized trial High or moderate Risk of bias
Inconsistency
Indirectness
Imprecision
Publication bias
Large effect
Dose response
All plausible confounding would reduce demonstrated 
effect or would suggest a spurious effect when results 
show no effect
Observational trial Low or very low
GRADE indicates Grading of Recommendations, Assessment, Development, and Evaluation.
Table 2. GRADE Terminology
Risk of bias Study limitations in randomized trials include lack of allocation concealment, lack of blinding, incomplete accounting of patients and 
outcome events, selective outcome reporting bias, and stopping early for benefit. Study limitations in observational studies include failure 
to apply appropriate eligibility criteria, flawed measurement of exposure and outcome, failure to adequately control confounding, and 
incomplete follow-up.
Inconsistency Criteria for inconsistency in results include the following: Point estimates vary widely across studies; CIs show minimal or no overlap; 
statistical test for heterogeneity shows a low P value; and the I2 is large (a measure of variation in point estimates resulting from among-
study differences).
Indirectness Sources of indirectness include data from studies with differences in population (eg, OHCA instead of IHCA, adults instead of children), 
differences in the intervention (eg, different CV ratios), differences in outcome, and indirect comparisons.
Imprecision Low event rates or small sample sizes will generally result in wide CIs and therefore imprecision.
Publication bias Several sources of publication bias include tendency not to publish negative studies and the influence of industry-sponsored studies. An 
asymmetrical funnel plot increases the suspicion of publication bias.
Good practice 
statements
Guideline panels often consider it necessary to issue guidance on specific topics that do not lend themselves to a formal review of research 
evidence. The reason might be that research into the topic is unlikely to be located or would be considered unethical or infeasible. 
Criteria for issuing a nongraded good practice statement include the following: There is overwhelming certainty that the benefits of the 
recommended guidance will outweigh harms, and a specific rationale is provided; the statements should be clear and actionable to a 
specific target population; the guidance is deemed necessary and might be overlooked by some providers if not specifically communicated; 
and the recommendations should be readily implementable by the specific target audience to whom the guidance is directed.
CV indicates compression-ventilation; GRADE, Grading of Recommendations, Assessment, Development, and Evaluation; IHCA, in-hospital cardiac arrest; and 
OHCA, out-of-hospital cardiac arrest. 
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findings are best regarded as associated with the CPR 
provided, or not, rather than necessarily caused by the 
interventions.
Systems: Studies Comparing Outcomes for Patients 
When DA-CPR Instruction Was Offered With 
Outcomes for Patients When DA-CPR Was Not Offered
For the comparison of outcomes in systems with DA-
CPR programs, we identified 16 studies. These included 
5 before-and-after studies17–21 and 11 cohort stud-
ies.22–32 Only 4 of these studies adjusted in some way for 
confounding variables.21,26,28,32 Table 3 provides a sum-
mary of the unadjusted and adjusted meta-analyses.
Survival With Favorable Neurological Outcomes. Six 
studies involving 50 395 patients reported survival 
with favorable neurological outcome at time points 
from hospital discharge to 6 months after cardiac 
arrest.18,21,22,26,28,32 The certainty of evidence was 
assessed as very low (downgraded for serious risk of 
bias, indirectness, and imprecision).
With the exception reported in 1 small series,28 sys-
tems offering DA-CPR were associated with increased 
favorable neurological outcome at 1 month after car-
diac arrest and at hospital discharge compared with 
systems not offering DA-CPR. These effects persisted 
after adjustment for confounding variables.
Survival Including All Neurological Outcomes. Nine 
studies including 20 938 patients addressed survival 
(regardless of neurological outcome) at time points 
such as hospital discharge and 1 month and 1 year after 
cardiac arrest.17–21,23,24,26,28 The certainty of evidence for 
these studies was assessed as very low, downgraded for 
serious risk of bias and imprecision.
With the exception reported in a single small se-
ries,28 systems offering DA-CPR were associated with 
increased survival at 1 month after cardiac arrest and at 
hospital discharge (Table 3) compared with systems not 
offering DA-CPR. These associations were strengthened 
after adjustment for confounding variables.
Short-Term Survival: ROSC, Hospital Admission. 
Eight studies including 45 474 patients addressed short-
term survival, including ROSC and survival to hospital 
admission.18,20–22,28–30,32 The certainty of evidence was 
assessed as very low, downgraded for serious risk of 
bias and imprecision.
With a single exception reported in a small series,21 
systems offering DA-CPR were associated with sus-
tained ROSC but not increased survival to hospital ad-
mission (Table 4) compared with systems not offering 
DA-CPR.
Bystander Delivery: Comparison of Outcomes From 
Patients Receiving DA-CPR Versus Those Receiving 
Either No Bystander CPR or Unassisted Bystander CPR
This evidence evaluation compared outcomes of pa-
tients who received bystander CPR as a result of DA-CPR 
with 2 groups of patients: those receiving no bystander 
CPR or those who received bystander CPR that was 
performed without dispatch assistance. Twenty obser-
vational cohort studies were identified,21,23,26–28,31–38,40–46 
Table 3. Systems: Studies Comparing Outcomes for Adults When DA-CPR Instruction Was Offered With Outcomes for Adults When DA-CPR Was 
Not Offered
Outcome
Unadjusted Analysis Adjusted Analysis
Studies 
(Patients), n
Evidence 
Certainty
 Odds Ratio 
(95% CI)
Absolute 
Difference
 Studies 
(Patients), n
Evidence 
Certainty
 Odds Ratio 
(95% CI)
Absolute 
Difference
Survival with 
favorable 
neurological 
outcome at 
1 mo
3 (44 698)21,26,32 Very low 1.10 (1.03–1.17) 9 more per 1000
(3–15 more)
2 (6799)21,26 Very low 1.47 (1.03–2.09) 11 more per 1000
(1–25 more)
Survival with 
favorable 
neurological 
outcome 
at hospital 
discharge
2 (5533)18,22 Very low 1.70 (1.21–2.37) 14 more per 1000
(4–27 more)
1 (5288)18 Very low 1.67 (1.13–2.47) 14 more per 1000
(3–30 more)
Survival at 
1 mo
2 (6799)21,26 Very low 1.20 (0.99–1.45) 11 more per 1000
(1 fewer–25 more)
2 (6799)21,26 Very low 1.45 (1.09–1.94) 25 more per 1000
(5–51 more)
Survival at 
hospital 
discharge
7 (14 139)17–20,23,24,28 Very low 1.23 (0.99–1.53) 33 more per 1000
(2 fewer–73 more)
1 (5288)18 Very low 1.33 (1.07–1.66) 21 more per 1000
(5–42 more)
Survival at 
hospital 
admission
6 (9548)18,20–22,29,30 Very low 1.08 (0.95–1.23) 12 more per 1000
(8 fewer–33 more)
1 (2493)21 Very low 0.97 (0.70–1.34) 4 fewer per 1000
(39 fewer–40 more)
ROSC 5 (49 229)18,20,21,28,32 Very low 1.17 (1.08–1.27) 27 more per 1000
(13–42 more)
1 (2493)21 Very low 1.14 (0.88–1.48) 26 more per 1000
(24 fewer–83 more)
DA-CPR indicates dispatcher-assisted cardiopulmonary resuscitation; and ROSC, return of spontaneous circulation.
D
ow
nloaded from
 http://ahajournals.org by on February 25, 2020
December 10, 2019 Circulation. 2019;140:e826–e880. DOI: 10.1161/CIR.0000000000000734e830
CL
IN
IC
AL
 S
TA
TE
M
EN
TS
  
AN
D 
GU
ID
EL
IN
ES
Soar et al 2019 ILCOR CoSTR Summary
but only 10 of these studies included adjusted analy-
sis.26,27,31–38 Because the clinical features of patients who 
received DA-CPR differed markedly from those of both 
the group who received no CPR and the group who re-
ceived bystander CPR without dispatch assistance, only 
adjusted outcomes are reported. Table  4 summarizes 
the study characteristics and results of the adjusted 
meta-analysis.
Receipt of DA-CPR Versus No Bystander CPR. 
Improvements in survival with favorable neuro-
logical function at hospital discharge31,33,34 and at 1 
month26 were reported among patients with OHCA 
who received bystander DA-CPR compared with 
those who received no bystander CPR. In addition, 
improved survival (regardless of neurological status) 
was reported at hospital discharge31,33,34,37,38 and at 1 
month.26 Recipients of DA-CPR were also more likely 
to achieve sustained ROSC than those who received 
no bystander CPR.34
Receipt of Bystander CPR With DA-CPR Versus 
Bystander CPR Without Dispatch Assistance 
(ie, Unassisted Bystander CPR). The findings 
were inconsistent when we compared patients who 
received bystander CPR with DA-CPR with patients 
who received bystander CPR that was performed 
without dispatch assistance. Survival with favorable 
neurological function did not differ either at hos-
pital discharge34 or at 1 month27 between patients 
who received bystander DA-CPR and those who 
received bystander CPR without dispatch assistance. 
Overall survival at hospital discharge did not differ 
between these groups,34 although survival at 1 month 
favored patients who received bystander DA-CPR.27,36 
Recipients of bystander DA-CPR were also more likely 
to have ROSC on hospital arrival than when bystander 
CPR was rendered without dispatch assistance.27 
Although these studies do not prove equivalence 
or noninferiority, they suggest that DA-CPR could 
possibly be as effective as spontaneously provided 
(unassisted) CPR.
Treatment Recommendations
We recommend that emergency medical dispatch cen-
ters have systems in place to enable call handlers to 
provide CPR instructions for adult patients in cardiac 
arrest (strong recommendation, very low certainty of 
evidence).
We recommend that emergency medical call-takers 
provide CPR instructions (when deemed necessary) for 
adult patients in cardiac arrest (strong recommenda-
tion, very low certainty of evidence).
Justification and Evidence to Decision Framework 
Highlights
Whereas the strength of these recommendations 
is greater than the certainty of the supporting evi-
dence, taken together, the preponderance of the 
evidence evaluated in this review suggests that 
clinical outcomes after OHCA are more likely to be 
improved when DA-CPR is available, offered, and 
provided. The similarity in outcomes when CPR is ini-
tiated spontaneously without the need for dispatch 
assistance (perhaps performed by a more skilled or 
trained bystander) and when DA-CPR is performed 
(perhaps with a less skilled or untrained bystander) 
exemplifies the potential positive impact of such 
point-of-care instruction. At a minimum, DA-CPR 
increases the likelihood that bystander CPR will be 
performed,3 itself an important predictor of favor-
able outcome from OHCA.47 The SR also found that 
DA-CPR favored not only bystander CPR but also 
time to CPR, ROSC, and initial shockable rhythm.3 
These considerations, along with the recognition 
that randomized clinical trials addressing this ques-
tion are unlikely to be forthcoming, led to the task 
force’s consensus that DA-CPR should be strongly 
recommended.
Table 4. Bystander Delivery: Comparison of Outcomes From Adults Receiving DA-CPR and Those Receiving No Bystander CPR or Unassisted 
Bystander CPR
Outcome
DA-CPR vs No CPR (Adjusted Analysis)
DA-CPR vs Unassisted Bystander CPR (Adjusted 
Analysis)
Studies (Patients), 
n
Evidence 
Certainty
Odds Ratio
(95% CI)
Studies 
(Patients), n
Evidence 
Certainty
Odds Ratio
(95% CI)
Survival with favorable neurological 
outcome at 1 mo
1 (4306)26 Very low 1.81 (1.23–2.67) 1 (78 112)27 Very low 1.00 (0.91–1.10)
Survival with favorable neurological 
outcome at hospital discharge
3 (35 921)33–35 Very low 1.54 (1.35–1.76) 1 (17 209)34 Very low 1.12 (0.94–1.34)
Survival at 1 mo 1 (4306)26 Very low 1.63 (1.32–2.01) 2 (78 697)27,36 Very low 1.13 (1.06–1.20)
Survival at hospital discharge 5 (43 550)33,34,37–39 Very low 1.40 (1.09–1.78) 1 (17 209)34 Very low 0.95 (0.83–1.09)
ROSC at hospital admission NA NA NA 1 (78 150)27 Very low 1.09 (1.04–1.14)
ROSC 1 (32 506)34 Very low 1.51 (1.32–1.73) 3 (34 811)32,34,36 Very low 1.04 (0.94–1.14)
CPR indicates cardiopulmonary resuscitation; DA-CPR, dispatcher-assisted cardiopulmonary resuscitation; NA, not applicable; and ROSC, return of spontaneous 
circulation.
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Knowledge Gaps
This evidence evaluation did not address training, lo-
gistical, operational, or economic issues pertaining to 
DA-CPR. The task force identified several knowledge 
gaps requiring further investigation, including the 
following:
• Optimal dispatcher training (and retraining) in rec-
ognizing OHCA and in providing DA-CPR
• The essential elements of a quality improvement 
program focused on DA-CPR
• The preferred CPR instruction sequence for 
DA-CPR
• The potential impact of dispatcher or call-taker’s 
background or prior experience (nonhealthcare 
professional versus paramedic or nurse) on DA-CPR 
performance
• The role of automated external defibrillators dur-
ing the course of DA-CPR
• The integration of adjunct technologies (eg, arti-
ficial intelligence or video) for clinical decision 
support
ADVANCED LIFE SUPPORT
Advanced Airway Interventions During 
Adult Cardiac Arrest
It is important to identify those airway interventions 
most likely to improve outcomes for both OHCA and 
IHCA. Chest compressions alone do not provide ade-
quate ventilation during prolonged cardiac arrest. Air-
way management is therefore required to facilitate ven-
tilation and to reduce the risk of gastric regurgitation 
and aspiration. The best airway strategy for improving 
patient outcomes is uncertain. On the basis of the evi-
dence available at the time, the 2015 CoSTR suggested 
using either an advanced airway or a bag-mask device 
for airway management during CPR (weak recommen-
dation, very low certainty of evidence) for cardiac arrest 
in any setting.48
Advanced airway management is common dur-
ing cardiac arrest. The American Heart Association 
Get With The Guidelines–Resuscitation registry of 
in-hospital cardiac arrest (IHCA) reports that 60% to 
70% of patients underwent tracheal intubation (TI) 
within the first 15 minutes of cardiac arrest.49 The US 
CARES registry (Cardiac Arrest Registry to Enhance 
Survival) of OHCA50 showed that 52% of patients 
underwent TI, 29% received a supraglottic airway 
(SGA), and in 18% no advanced airway was insert-
ed. In the recent AIRWAYS-2 RCT (Effect of a Strat-
egy of a Supraglottic Airway Device Versus Tracheal 
Intubation During Out-of-Hospital Cardiac Arrest on 
Functional Outcome),51 which compared i-gel (Inter-
surgical Ltd, Berkshire, UK) with TI for OHCA, 17.3% 
of patients did not receive an advanced airway.
Since 2015, 3 new RCTs investigating airway man-
agement during cardiac arrest have been published.51–53 
This topic was given a high priority for review by the 
ILCOR ALS Task Force, and ILCOR commissioned an SR 
to identify and analyze all published evidence on ad-
vanced airway interventions during OHCA and IHCA.4 
The ALS Task Force analyzed and discussed the SR and 
all of the studies identified by the SR. A draft ALS CoSTR 
for advanced airway interventions during cardiac arrest 
was posted online on March 20, 2019, and included 
the data reviewed and draft treatment recommenda-
tions with comments accepted through April 4, 2019.54 
There were 6798 visits and 16 posted comments during 
the 2-week comment period. The ALS Task Force re-
viewed all comments and, in the light of these, reevalu-
ated and finalized the draft CoSTR.
Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Adults any setting (in-hospital or out-of-
hospital) with cardiac arrest from any cause
Intervention: A specific advanced airway manage-
ment method (eg, TI or an SGA device) during cardiac 
arrest
Comparators: A different advanced airway manage-
ment method or no advanced airway management 
method (eg, bag-mask ventilation [BMV]) during car-
diac arrest
Outcomes: Survival to hospital discharge/28 days 
with favorable neurological outcome and survival to 
hospital discharge/28 days ranked as critical outcomes; 
ROSC ranked as an important outcome
Study designs: RCTs and nonrandomized studies 
(non-RCTs, interrupted time series, controlled before-
and-after studies, cohort studies) that compared at 
least 2 airway strategies eligible for inclusion; studies 
with ≤10 patients in either group excluded
Time frame: All years and all languages included; 
unpublished studies (eg, conference abstracts, trial pro-
tocols) excluded; literature search updated to October 
30, 2018
PROSPERO registration: CRD42018115556
Consensus on Science
Seventy-one observational studies with 121 combina-
tions of different airway management strategies were 
included in the SR.4 Of the 71 comparative studies, 
61 included OHCA, 9 included IHCA, and 1 combined 
both. Because of the risk of bias, heterogeneity be-
tween studies, and the availability of RCTs, no meta-
analyses were performed for observational studies.
The SR identified 11 controlled trials of airway man-
agement in patients with OHCA.51–53,55–62 Of these, 8 
were phase 2/feasibility trials with small sample sizes, 
generally with a high risk of bias, including some that 
were published >15 years ago.55–62 Therefore, only 3 
trials, all published in 2018, were used for the SR be-
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cause they were larger and powered for more relevant 
outcomes.51–53 Because of different comparisons and 
heterogeneity, no meta-analyses of these RCTs were 
undertaken (Table 5).
Jabre et al52 compared BMV with TI in a physician-
based system, whereas Benger et al51 and Wang et al53 
compared SGA devices with TI in non–physician-based 
systems. The TI success rates were 98% in the Jabre et 
al trial, 70% in the Benger et al trial, and 52% in the 
Wang et al trial. Success rates were not defined identi-
cally in the 3 studies; this led to concerns about gen-
eralizability of the findings. As a result, the task force 
considered 2 different settings when evaluating the 
overall certainty of evidence (ie, the GRADE approach): 
a setting with a low TI success rate (similar to the sys-
tems in the Benger et al and Wang et al studies) and a 
setting with a high TI success rate (similar to the Jabre 
et al system).
Overall, there is no high-certainty evidence to rec-
ommend an advanced airway strategy over BMV and 
no high-certainty evidence to recommend a specific ad-
vanced airway device over another (Table 5).
Treatment Recommendations
We suggest using BMV or an advanced airway strat-
egy during CPR for adult cardiac arrest in any setting 
(weak recommendation, low to moderate certainty of 
evidence).
If an advanced airway is used, we suggest an SGA for 
adults with OHCA in settings with a low TI success rate 
(weak recommendation, low certainty of evidence).
If an advanced airway is used, we suggest an SGA 
or TI for adults with OHCA in settings with a high TI 
success rate (weak recommendation, very low certainty 
of evidence).
If an advanced airway is used, we suggest an SGA 
or TI for adults with IHCA (weak recommendation, very 
low certainty of evidence).
Justification and Evidence to Decision Framework 
Highlights
This topic was given high priority by the ILCOR ALS 
Task Force, following the publication of 3 new RCTs51–53 
since the previous CoSTR in 2015.48,63
The 3 new RCTs have enabled the ALS Task Force 
to provide more specific treatment recommendations. 
The 2015 treatment recommendation was based on 
evidence from only observational studies with critical or 
serious risk of bias, primarily confounding and selection 
bias.48,63
There is currently no supporting evidence that an 
advanced airway (ie, SGA or TI) during CPR improves 
survival or survival with a favorable neurological/func-
tional outcome after adult cardiac arrest in any setting 
compared with BMV.
This ILCOR 2019 CoSTR addresses airway manage-
ment during CPR in adults; it does not address airway 
management after ROSC. After ROSC, survivors requir-
ing mechanical ventilation and postresuscitation care 
will eventually require TI.
We have used the term advanced airway strategy 
because advanced airway device placement usually 
starts with a variable period of BMV. The timing and 
reasons for transitioning to an advanced airway device 
will vary, depending on the clinical scenario. In the 3 
recent RCTs,51–53 patients treated with advanced airways 
had a period of BMV while providers prepared for de-
vice insertion; in some patients, an SGA was inserted 
as the first airway intervention without BMV. The term 
advanced airway strategy includes all of these options.
We have not provided a precise value or range of 
values for low and high intubation success rate or an 
agreed-on definition. Studies have used different defi-
nitions of TI success. We considered the Wang et al53 
and Benger et al51 RCTs as having a low TI success rate 
(51.6% and 69.8%, respectively) and the Jabre et al52 
RCT as having a high success rate (97.9%).
We assumed that TI success rates are high in the 
in-hospital setting, but there is limited evidence to sup-
port this, and success is likely to be site dependent. 
The recommendations for IHCA are based primarily on 
indirect evidence from the OHCA studies. There are 
no airway RCTs for IHCA, and the task force did con-
sider the findings of 1 large (n=71 615) observational 
study of IHCA that TI within any given minute during 
the first 15 minutes of resuscitation, compared with 
no intubation during that minute, was associated with 
decreased survival to hospital discharge.49 This study 
used a time-dependent propensity score but did not 
eliminate confounding by indication and provided only 
very-low-certainty evidence.
We have not expressed a preference for a particular 
SGA device of those currently available (i-gel was used 
in the Benger et al51 RCT, and the Laryngeal Tube [VBM 
Medizintechnik GmbH, Sulz am Neckar, Germany] was 
used in the Wang et al53 RCT). The performance of in-
dividual SGA devices varies; therefore, we did not pool 
data from these 2 studies.
BMV can be difficult to perform, and effectiveness 
varies according to provider skills. We have not evalu-
ated the optimal bag-mask technique (eg, 1-person or 
2-person methods) and the use of adjuncts such as oro-
pharyngeal or nasopharyngeal airways.
The task force considered that the preferred airway 
option is likely to depend on the skills of the provider 
and the specific patient circumstances. In addition, pa-
tients may require different airway interventions at dif-
ferent stages of resuscitation.
ALS Task Force Knowledge Gaps
The task force identified several knowledge gaps re-
quiring further investigation:
• A prospective comparison of BMV with SGA use
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• The optimal airway management strategy for IHCA
• The impact on outcome of using an advanced air-
way (SGA or TI) without prior BMV
• The optimal SGA for use during cardiac arrest
• The optimal time point during CPR to change to 
different airway techniques
• The impact of different airway strategies on CPR 
quality (no-flow time), as well as oxygenation and 
ventilation during CPR
• The training and clinical experience required to 
maintain proficiency in an airway technique
Use of Vasopressors in Cardiac Arrest
Vasopressors have been used in CPR since animal ex-
periments in the 1960s, despite a lack of RCT evi-
dence in humans at the time.64,65 In the past 20 years, 
several human RCTs have provided evidence for va-
sopressor use for cardiac arrest. ILCOR has reviewed 
the use of vasopressors regularly, with the most re-
cent update in 2015.48,63 The ILCOR ALS Task Force 
targeted the current update after the 2018 publica-
tion of a new large RCT on the use of epinephrine 
in OHCA.66 This updated CoSTR summary is derived 
from an ILCOR-commissioned SR and meta-analysis 
completed in 2019.5 The ALS Task Force analyzed and 
discussed the SR and all of the studies identified by 
the SR. A draft CoSTR for vasopressors in cardiac ar-
rest was posted online on March 20, 2019, and in-
cluded the data reviewed and draft treatment recom-
mendations with comments accepted through April 
4, 2019.67 This site was viewed 3861 times during 
the comment period, and 6 comments were posted. 
The ALS Task Force reviewed the comments and, in 
light of these comments, reevaluated and finalized 
the draft CoSTR.
Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Adults (age >18 years) with cardiac arrest in 
any setting (out of hospital or in hospital)
Intervention: Vasopressor or a combination of vaso-
pressors provided intravenously or intraosseously dur-
ing CPR
Comparators: No vasopressor, a different vasopres-
sor, or a combination of vasopressors provided intrave-
nously or intraosseously during CPR
Outcomes: Short-term survival (ROSC and survival 
to hospital admission), midterm survival (survival to 
hospital discharge, 28 days, 30 days, or 1 month), mid-
term favorable neurological outcomes (Cerebral Perfor-
mance Category [CPC] 1–2 or modified Rankin Scale 
score 0–3 at hospital discharge, 28 days, 30 days, or 
1 month), and long-term unfavorable and poor (modi-
fied Rankin Scale score 4–5) neurological outcomes 
(after 1 month)
Study designs: Randomized trials, nonrandomized tri-
als, and observational studies (cohort and case-control 
studies) with a comparison group included
Time frame: From inception of databases to Novem-
ber 23, 2018
PROSPERO registration: CRD42018116989
Consensus on Science
Epinephrine Compared With Placebo
For the comparison of epinephrine with placebo, there 
are 2 RCTs with a total of >8500 patients with OHCA 
Table 5. Summary of the Evidence From the 3 RCTs Studying Adult Advanced Airway Management During Cardiac Arrest
Study, Year Intervention Comparator Setting Outcome
Risk Difference 
(95% CI) Certainty in Evidence
Wang et al,53 
2018
Laryngeal tube TI OHCA Survival to hospital 
discharge
27 more per 
1000
(6–48 more)
Low in low TI success setting (OHCA)
Very low in high TI success setting (OHCA)
Very low (IHCA)
Wang et al,53 
2018
Laryngeal tube TI OHCA Survival to hospital 
discharge with a favorable 
neurological outcome
21 more per 
1000
(3–38 more)
Low in low TI success setting (OHCA)
Very low in high TI success setting (OHCA)
Very low (IHCA)
Benger et al,51 
2018
i-gel TI OHCA Survival to hospital 
discharge
4 fewer per 1000
(14 fewer–8 
more)
Low in low TI success setting (OHCA)
Very low in high TI success setting (OHCA)
Very low (IHCA)
Benger et al,51 
2018
i-gel TI OHCA Survival to hospital 
discharge with a favorable 
neurological outcome
6 more per 1000
(16 fewer–4 
more)
Low in low TI success setting (OHCA)
Very low in high TI success setting (OHCA)
Very low (IHCA)
Jabre et al,52 
2018
BMV TI OHCA 28-d survival 1 more per 1000
(18 fewer–21 
more)
Low in low TI success setting (OHCA)
Moderate in high TI success setting (OHCA)
Low (IHCA)
Jabre et al,52 
2018
BMV TI OHCA 28-d survival with a 
favorable neurological 
outcome
1 more per 1000
(13 fewer–23 
more)
Low in low TI success setting (OHCA)
Moderate in high TI success setting (OHCA)
Low (IHCA)
BMV indicates bag-mask ventilation; IHCA in-hospital cardiac arrest; OHCA, out-of-hospital cardiac arrest; RCT, randomized controlled trial; and TI, tracheal 
intubation.
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that provide evidence on our critical and important 
outcomes66,68 but no RCTs of IHCA. The PARAMEDIC2 
trial (A Randomized Trial of Epinephrine in Out-of-
Hospital Cardiac Arrest) is a recent RCT that random-
ized ≈8000 patients with OHCA managed by para-
medics in the United Kingdom,66 and the PACA trial 
(Placebo-Controlled Trial of Adrenaline in Cardiac Ar-
rest) randomized ≈500 patients with OHCA managed 
by paramedics in Western Australia.68 A meta-analysis 
of these studies was conducted to update the CoSTR 
for epinephrine use during CPR.5
The findings of the SR and meta-analysis for all ini-
tial rhythms are summarized in Table 6. Only the most 
recent study reported 3-month survival.66 That study 
found a statistically significant increase in survival at 3 
months in the epinephrine group but no statistical dif-
ferences in survival with favorable or unfavorable neu-
rological outcome at 3 months. The meta-analysis of 
the 2 studies found no benefit in favorable neurological 
outcome at discharge but showed higher rates of sur-
vival to discharge, survival to admission, and ROSC in 
the epinephrine group.66,68
In the subgroup of patients with nonshockable 
rhythms, combined evidence from the 2 RCTs showed 
benefit of epinephrine for survival to discharge (mod-
erate certainty; RR, 2.56 [95% CI, 1.37–4.80]; ARD, 
0.6% [95% CI, 0.1–1.5]) and ROSC (high certainty; RR, 
4.45 [95% CI, 3.91–5.08]; ARD, 25.4% [95% CI, 21–
30]).66,68 There was no difference in survival to discharge 
with favorable neurological outcome (low certainty).66 
In data pending publication from the larger, more re-
cent trial, the subgroup with nonshockable rhythms 
showed no difference in survival to 3 months with 
favorable neurological outcome, although this result 
approached significance (very low certainty; RR, 3.03 
[95% CI, 0.98–9.38]; ARD, 0.3% [95% CI, 0–1.1]).66,69
In the subgroup of patients with shockable rhythms, 
combined evidence from the 2 RCTs showed benefit 
of epinephrine for ROSC (moderate certainty; RR, 1.68 
[95% CI, 1.48–1.92]; ARD, 18.5% [95% CI, 13.0–
25.0]) but no difference for survival to discharge.66,68 In 
data pending publication from the larger, more recent 
trial, the subgroup with shockable rhythms showed no 
difference in survival to 3 months with favorable neuro-
logical outcome.69
Vasopressin Compared With Epinephrine
Three RCTs with >1500 patients with OHCA com-
pared vasopressin with epinephrine; all were pub-
lished >10 years ago.70–72 The combined results of 
these studies showed no benefit of vasopressin com-
pared with epinephrine across all outcomes and ini-
tial rhythms.
One RCT included 200 patients with IHCA ran-
domized to vasopressin or epinephrine with any initial 
rhythm and showed no benefit from the use of vaso-
pressin compared with epinephrine.73
Initial Epinephrine Plus Vasopressin Compared With 
Epinephrine Only
Three RCTs with >3000 patients with OHCA compared 
epinephrine plus vasopressin with epinephrine only; all 
were published >8 years ago.74–76 The combined results 
of these studies showed no benefit across all outcomes 
and initial rhythms. There were no in-hospital studies of 
this comparison.
Treatment Recommendations
We recommend administration of epinephrine during 
CPR (strong recommendation, low to moderate cer-
tainty of evidence).
For nonshockable rhythms (pulseless electrical activi-
ty/asystole), we recommend administration of epineph-
rine as soon as feasible during CPR (strong recommen-
dation, very low certainty of evidence).
For shockable rhythms (ventricular fibrillation/pulse-
less ventricular tachycardia), we suggest administration 
of epinephrine after initial defibrillation attempts are 
unsuccessful during CPR (weak recommendation, very 
low certainty of evidence).
We suggest against the administration of vasopres-
sin in place of epinephrine during CPR (weak recom-
mendation, very low certainty of evidence).
Table 6. RR and ARD for Each Outcome With Epinephrine Compared With Placebo
Study, Year Outcome RR (95% CI)
ARD  
(95% CI) Certainty in Evidence
Perkins et al,66 2018 Favorable neurological outcome at 3 mo 1.30 (0.94–1.80) 5 more per 1000  
(1 fewer–13 more)
Low
Perkins et al,66 2018 Survival at 3 mo 1.40 (1.07–1.84) 9 more per 1000  
(2–18 more)
Moderate
Jacobs et al,68 2011
Perkins et al,66 2018
Favorable neurological outcome at hospital discharge 1.21 (0.90–1.62) 4 more per 1000  
(2 fewer–12 more)
Moderate
Jacobs et al,68 2011
Perkins et al,66 2018
Survival to hospital discharge 1.44 (1.11–1.86) 10 more per 1000  
(2–19 more)
Moderate
Jacobs et al,68 2011
Perkins et al,66 2018
ROSC 3.09 (2.82–3.39) 243 more per 1000  
(211–277 more)
High
ARD indicates absolute risk difference; ROSC, return of spontaneous circulation; and RR, relative risk.
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We suggest against the addition of vasopressin to 
epinephrine during CPR (weak recommendation, low 
certainty of evidence).
Justification and Evidence to Decision  
Framework Highlights
The ILCOR ALS Task Force prioritized this population, 
intervention, comparator, outcome, study design, and 
time frame after the recent publication of a large RCT 
comparing administration of epinephrine with placebo 
in >8000 patients with OHCA.66 The collective evidence 
from the recent trial and a small earlier RCT showed 
that epinephrine for OHCA increases ROSC, survival to 
discharge, and survival at 3 months, but epinephrine 
has not been shown definitively to increase survival to 
discharge with favorable neurological outcome.5,66,68 
The more recent trial, which was also the only one re-
porting outcomes at 3 months, found no difference in 
survival with favorable or unfavorable neurological out-
come at the 3-month time point.66 The lack of statisti-
cal difference in survival with favorable and unfavorable 
outcome at 3 months may reflect the low event rates for 
these outcomes and the consequent failure to achieve 
the optimal sample size for these outcomes, resulting in 
low power to detect a difference. The increase in surviv-
al with favorable neurological outcome at 3 months ap-
proaches statistical significance for nonshockable initial 
rhythms, with the lower limit of the CI being very close 
to 1. Whether the difference in neurological outcome 
would be larger in a patient population with higher 
overall survival than that seen in the PARAMEDIC2 trial 
is unknown. A very high value is placed on the appar-
ent life-preserving benefit of epinephrine, even if the 
absolute effect size is likely to be small. Although the 
PARAMEDIC2 study raised concerns about increasing 
the number of survivors with unfavorable neurological 
outcome, the opinion of the ALS task force is that the 
data at 3 months do not support this assertion. Overall, 
the impact of epinephrine administration on neurologi-
cal outcome for patients with OHCA remains uncertain, 
but the available data are more suggestive of benefit 
than harm. Whether the administration of epinephrine 
earlier than in the available OHCA trials would have a 
larger beneficial effect also remains uncertain but is 
suggested by observational data. That stated, the ALS 
Task Force acknowledged the importance of consider-
ing the cost burden incurred with a potential increase in 
short-term survival with unfavorable neurological out-
come. Conversely, an increase in ROSC may allow the 
development of other treatments to prevent or mitigate 
neurological injury. The opportunity for families to see 
patients before death and the possibility for organ do-
nation were additional potential benefits of the increase 
in short-term survival that were considered. The task 
force recognized that different healthcare systems and 
different cultures may weigh these costs and benefits 
differently. A formal cost-effectiveness analysis was not 
performed, and this remains a knowledge gap.
The use of vasopressin alone or in combination with 
epinephrine was not shown to be beneficial compared 
with epinephrine alone; thus, epinephrine alone is rec-
ommended because it reduces complexity.
There is a statistically significant benefit of standard-
dose epinephrine compared with placebo on survival 
to hospital discharge in patients with OHCA with non-
shockable initial rhythms but not in those with shock-
able initial rhythms (although epinephrine improved 
ROSC in all rhythms). Because these are subgroup com-
parisons, however, and were not separately random-
ized, the results should be interpreted with some cau-
tion. For example, the lack of a statistically significant 
difference in shockable rhythms may result from inad-
equate power because there were far fewer patients 
in this subgroup than in the nonshockable rhythms 
groups.
In most cases of nonshockable rhythms, there are 
limited alternative interventions, and survival is very 
poor unless a reversible cause is identified and treated. 
Therefore, we recommend provision of epinephrine as 
soon as feasible in cardiac arrest with nonshockable 
rhythms. Exceptions may exist when a clear reversible 
cause can be addressed rapidly.
The optimal timing for epinephrine in patients with 
shockable rhythms is unknown. The studies evaluating 
administration of epinephrine used protocols for epi-
nephrine administration after the third shock. The task 
force agrees that it seems prudent to wait to adminis-
ter epinephrine until initial defibrillation attempts have 
been unsuccessful. However, the optimal timing and 
number of shocks after which epinephrine should be 
administered remain unclear.
There are also very limited data to guide the specific 
dosing of epinephrine during CPR. The 2 OHCA RCTs 
comparing epinephrine with placebo used standard-dose 
epinephrine (1 mg intravenously or intraosseously every 
3–5 minutes). Although this CoSTR did not separately 
evaluate high-dose epinephrine because no new evidence 
was found, a previous ILCOR review did not find evidence 
of a survival benefit for high-dose epinephrine. Thus, the 
evidence to date supports the dosing used in the 2 RCTs 
included in the meta-analysis in the current review.
There is limited RCT evidence on the use of epi-
nephrine for IHCA. No studies have assessed the use of 
standard-dose epinephrine compared with placebo in 
the in-hospital setting, and only 1 study examined the 
use of vasopressin compared with epinephrine.77 There 
was no statistical benefit or harm from the administra-
tion of vasopressin compared with epinephrine for in-
hospital CPR. Therefore, using the evidence for OHCA, 
the ILCOR ALS Task Force decided to make the same 
recommendations for epinephrine administration for 
IHCA and OHCA.
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ALS Task Force Knowledge Gaps
With the recent publication of a large RCT comparing 
epinephrine with placebo in OHCA, we have greater 
confidence in the benefit of epinephrine for survival to 
discharge and ROSC. However, the effect of epineph-
rine on neurological outcomes is still uncertain and 
remains an important knowledge gap. The task force 
identified several other knowledge gaps requiring fur-
ther investigation:
• The long-term neurological benefit of epinephrine 
in cardiac arrest
• The optimal dose of epinephrine and dosing 
interval
• The use and optimal timing of epinephrine admin-
istration in patients with shockable rhythms
• The use of epinephrine for IHCA
• The cost-effectiveness of epinephrine
• The effect of different routes of administration 
(intravenous versus intraosseous)
• The effect of increased ROSC on organ donation
• Effective therapies to prevent or mitigate against 
neurological injury associated with cardiac arrest
ECPR for Cardiac Arrest: Adults
ECPR is used to support circulation in patients with 
cardiac arrest refractory to conventional CPR.78 ECPR 
maintains vital organ perfusion while potential revers-
ible causes of the cardiac arrest can be identified and 
treated. ECPR can be considered in select patients when 
rapid expert deployment is possible; however, the opti-
mal patient selection and timing of the therapy are not 
well defined. An SR was undertaken by ILCOR to assess 
the effectiveness of ECPR, compared with manual or 
mechanical CPR, for OHCA and IHCA of all causes in 
adults and children.6 A draft CoSTR posted for public 
comment was viewed 1169 times in the 2-week com-
ment period.79 The task force reviewed the 4 posted 
comments and considered the suggestions when final-
izing the Justification and Evidence to Decision Frame-
work Highlights section.
Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Adults (age  ≥18 years) and children 
(age <18 years) with cardiac arrest in any setting (out of 
hospital or in hospital)
Intervention: ECPR, including extracorporeal mem-
brane oxygenation (ECMO) or cardiopulmonary bypass, 
during cardiac arrest
Comparator: Manual CPR and/or mechanical CPR
Outcomes: Clinical outcomes, including short-term 
survival and neurological outcomes (eg, hospital dis-
charge, 28 days, 30 days, and 1 month) and long-term 
survival and neurological outcomes (eg, 3 months, 6 
months, and 1 year)
Study design: Randomized trials, non-RCTs, and 
observational studies (cohort studies and case-control 
studies) with a control group included; animal studies, 
ecological studies, case series, case reports, reviews, ab-
stracts, editorials, comments, and letters to the editor 
not included
Time frame: All years and all languages included
PROSPERO registration: CRD42018085404
Note: The pediatric information is summarized in a 
later section of this document (see the ECPR: Infants 
and Children section).
Consensus on Science
No randomized clinical trials were identified. Selected 
summary data are included in Table 7. Fifteen of the in-
cluded studies were in adult OHCA.80,82,85,87–89,91–94,97–101 
Three studies included both patients with OHCA and 
those with IHCA.82,89,99 Most studies defined the expo-
sure as ECPR use; 1 study93 defined the exposure as ECPR 
availability; and 2 studies100,101 defined the exposure as an 
ECPR strategy. Twelve studies reported survival to hospital 
discharge80,82,85,87–89,91–93,97–99; 6 studies reported long-term 
survival82,88,91,93,97,98; 8 studies reported favorable neuro-
logical outcome at hospital discharge85,87,88,92,93,97,100,101; 
and 6 studies reported long-term favorable neurological 
outcomes.88,91,93,94,97,98
Seven of the included studies were in adult 
IHCA.81,83,84,86,90,95,96 Most of these studies defined the 
exposure as ECPR use, although 2 studies95,96 defined 
the exposure as an ECPR attempt. Six studies report-
ed survival to hospital discharge81,83,86,90,95,96; 6 stud-
ies reported long-term survival81,83,86,90,95,96; 5 studies 
reported favorable neurological outcome at hospital 
discharge81,83,90,95,96; and 5 studies reported long-term 
favorable neurological outcome.81,83,90,95,96 Four stud-
ies reported survival analyses with length of follow-up 
ranging from 1 to 3 years.81,83,84,90
For studies in both OHCA and IHCA, the overall cer-
tainty of evidence was rated as very low for all out-
comes. All individual studies were at a very serious risk 
of bias, mainly because of confounding. As a result of 
this confounding and a high degree of heterogeneity, 
no meta-analyses could be performed, and individual 
studies are difficult to interpret.
Treatment Recommendations
We suggest that ECPR may be considered as a rescue 
therapy for selected patients with cardiac arrest when 
conventional CPR is failing in settings in which it can 
be implemented (weak recommendation, very low cer-
tainty of evidence).
Justification and Evidence to Decision Framework 
Highlights
In making this weak recommendation, we have con-
sidered the extremely high mortality rate of patients 
with cardiac arrest, particularly when the arrest is 
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Table 7. Summary of Adult ECPR Studies
Study, Year Country
Years of 
Patient 
Inclusion
IHCA vs 
OHCA Inclusion Criteria
Patients 
Analyzed, 
n
Covariates Included 
in Adjusted Analysis
Hospital Discharge/1 mo
Exposed, 
n (%)
Unexposed, 
n (%)
Adjusted 
Results, OR 
or RR (95% 
CI)
Agostinucci 
et al,80 2011
France 2005–2010 OHCA Use of load-
distributing band
285 NA 0/27 (0) 3/258 (1) NR
Blumenstein 
et al,81 2015
Germany 2009–2013 IHCA Cardiovascular 
admission, witnessed
353 Age, APACHE II score, 
CPR duration, obesity, 
dyslipidemia, coronary 
artery disease, lactate, 
creatine kinase, eGFR, 
creatinine, ICU, OR, 
dose of norepinephrine
14/52 (27) 9/52 (17) 1.76  
(0.68–4.53) 
(calculated)
Cesana et 
al,82 2018
Italy 2011–2015 Combined Age 18–75 y, witnessed, 
proven ischemic origin, 
absence of severe 
comorbidities that 
would have precluded 
ICU admission and 
conditioning in the 
short-term prognosis
148 NA 13/63 (21) 49/85 (58) NR
Chen et al,83 
2008
Taiwan 2004–2006 IHCA Age 18–75 y, CPR 
for >10 min, cardiac 
origin, witnessed
92 Age, sex, initial cardiac 
rhythm, time point of 
CPR, CPR duration, 
comorbidities
15/46 (33) 8/46 (17) 2.30  
(0.86–6.13) 
(calculated)
Cho et al,84 
2014
Korea 2001–2013 IHCA Pulmonary embolism 20 Hypertension, CPR 
duration
NR NR NR
Choi et al,85 
2016
Korea 2011–2015 OHCA Nontraumatic, age ≤75 
y, witnessed cardiac 
arrest, bystander 
administration of CPR 
or no-flow time ≤5 
min, prehospital low-
flow time ≤30 min and 
refractory arrest >10 
min of conventional 
CPR in the ED, known 
absence of severe 
comorbidities that 
preclude admission to 
the intensive care unit
60 NA 3/10 (30) 4/50 (8) NR
Chou et al,86 
2014
Taiwan 2006–2010 IHCA Age >18 y, acute 
myocardial infarction in 
the ED, CPR for >10 min
66 NA NR NR 1.93  
(0.60–6.23) 
(unadjusted)
Hase et al,87 
2005
Japan 1999–2003 OHCA Presumed cardiac 
cause
100 NA 13/38 (34) 27/62 (44) NR
Kim et al,88 
2014
Korea 2006–2013 OHCA Age >18 y, not 
traumatic
104 Age, sex, comorbidity 
score, bystander CPR, 
witnessed cardiac arrest, 
first documented arrest 
rhythm, presumed 
cause of arrest, 
interval from arrest to 
CPR started by EMS 
provider, CPR duration, 
and therapeutic 
hypothermia
9/52 (17) 11/52 (21) 0.78  
(0.29–2.08) 
(calculated)
Lee et al,89 
2015
Korea 2009–2014 Combined NR 955 Age, main diagnosis, 
location, CPR 
duration, initial 
rhythm, hypertension, 
malignancy, stroke, 
chronic renal failure, 
cardiovascular disease
18/81 (22) 120/874 (14) 0.37  
(0.13–1.06)
(Continued )
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Lin et al,90 
2010
Taiwan 2004–2006 IHCA Age 18–75 y, cardiac 
origin, CPR duration 
>10 min, ROSC
54 Age, sex, initial 
rhythm, CPR duration, 
timing and location, 
comorbidities (diabetes 
mellitus, hypertension, 
dyslipidemia, 
malignancy, COPD, 
cardiovascular or 
cerebrovascular, 
abnormal liver 
function, dialysis)
8/27 (30) 5/27 (19) 1.85 
(0.52–6.63) 
(calculated)
Maekawa et 
al,91 2013
Japan 2000–2004 OHCA Presumed cardiac 
origin, age >16 
y, witnessed, CPR 
duration >20 min
48 Not clear but probably 
age, sex, activities of 
daily living, location of 
OHCA, bystander CPR, 
initial rhythm, number 
of shocks, airway 
insertion, venous 
access, physician-
staffed ambulance, 
ROSC during transport, 
times, TTM, IABP, PCI, 
CPR duration, time 
from arrest to ALS
9/24 (38) 3/24 (13) 4.20 
(0.97–18.2) 
(calculated)
Poppe et al,92 
2015
Austria 2013–2014 OHCA Age >18 y, ongoing 
CPR
96 NA 2/12 (17) 8/84 (10) NR
Sakamoto et 
al,93 2014
Japan 2008–2011 OHCA Shockable rhythm, 
cardiac arrest on 
arrival, within 45 min 
from reception of the 
emergency call or the 
onset of cardiac arrest 
to the hospital arrival, 
no ROSC at least 
during the 15 min 
after hospital arrival
454 NA 69/260 
(27)
12/193 (6) NR
Schober et 
al,94 2017
Austria 2002–2012 OHCA Cardiac origin, CPR 
duration >30 min
239 NA NR NR NR
Shin et al,95 
2011,
Shin et al,96 
2013
Korea 2003–2009 IHCA Age 18–80 y, CPR 
duration >10 min, 
witnessed
120 Age, sex, 
comorbidities, clinical 
situation, cause of the 
arrest, location, year, 
time during day and 
week, initial rhythm, 
CPR duration, prearrest 
SOFA score, Deyo-
Charlson score, post-
CPR variables
19/60 (32) 6/60 (10) 4.17 
(1.53–11.4) 
(calculated)
Siao et al,97 
2015
Taiwan 2011–2013 OHCA Age 18–75 y, 
ventricular fibrillation, 
no-flow <5 min, 
refractory cardiac 
arrest
60 Age, CPR duration, 
defibrillation, female 
sex, use of therapeutic 
hypothermia
10/20 (50) 11/40 (28) 4.10  
(0.79–21.3)
Tanno et al,98 
2008
Japan 2000–2004 OHCA Age >16 y, cardiac 
origin
398 NA 14/66 (21) 25/332 (8) NR
Venturini et 
al,99 2017
United 
States
2011–2016 Combined CPR in cardiac 
catheterization 
laboratory, mechanical 
chest compression
31 NA 1/14 (7) 3/17 (18) NR
Table 7. Continued
Study, Year Country
Years of 
Patient 
Inclusion
IHCA vs 
OHCA Inclusion Criteria
Patients 
Analyzed, 
n
Covariates Included 
in Adjusted Analysis
Hospital Discharge/1 mo
Exposed, 
n (%)
Unexposed, 
n (%)
Adjusted 
Results, OR 
or RR (95% 
CI)
(Continued )
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refractory to standard advanced cardiac life support 
interventions (ie, cardiac arrest when conventional 
CPR is failing). Therefore, the potential for benefit 
and the value of this intervention remain despite the 
overall low certainty of supporting evidence and lack 
of randomized trials.
The published studies used select patients for ECPR, 
not the general population of all cardiac arrest cases. 
Guidelines for ECPR use in clinical practice should ide-
ally apply to similar populations, although RCTs have 
not been performed to define the optimal population.
We acknowledge that ECPR is a complex interven-
tion that requires considerable resources and training 
that are not universally available, but we also acknowl-
edge the value of an intervention that may be success-
ful in individuals in whom usual CPR techniques have 
failed. ECPR can sustain perfusion while another inter-
vention such as coronary angiography and percutane-
ous coronary intervention can be performed.
ALS Task Force Knowledge Gaps
There are currently no published randomized trials of 
ECPR, although several are pending. The task force 
identified several knowledge gaps requiring further in-
vestigation:
• The optimal post–cardiac arrest care strategy for 
patients resuscitated with ECPR
• The patient groups most likely to benefit from 
ECPR
• The optimal ECPR techniques
• The optimal timing to initiate ECPR during resusci-
tation (ie, early, late, when in the sequence)
• The potential role of ECPR during the periarrest 
period
• The population-specific differences in indications 
for ECPR for IHCA and OHCA
• The differences in quality of life (QOL) between 
survivors of ECPR and survivors of conventional 
CPR
• The cost-effectiveness of ECPR
PEDIATRIC LIFE SUPPORT
The Pediatric Life Support Task Force reviewed 4 topics 
for this 2019 CoSTR: DA-CPR, advanced airway inter-
ventions in pediatric cardiac arrest, ECMO CPR (ECPR), 
and TTM during post–cardiac arrest care. An SR was 
published for each of these topics.3,6–8 The Pediatric Life 
Support Task Force then reviewed the SR and the stud-
ies identified by the SR and generated a CoSTR that 
was posted on the ILCOR website for public comments 
for each topic. This document contains a summary of 
the 4 CoSTRs, including information about task force 
deliberations and insights.
Yannapoulos 
et al,100 2016
United 
States
2015–2016 OHCA Age 18–75 y, cardiac 
cause, initial shockable 
rhythm, minimum 3 
direct-current shocks 
without ROSC, received 
amiodarone 300 mg, 
eligible for mechanical 
CPR, transfer time from 
scene to catheterization 
laboratory <30 min
188 NA 10/18 (53) NR NR
Yannapoulos 
et al,101 2017
United 
States
2015–2016 OHCA Age 18–75 y, cardiac 
cause, initial shockable 
rhythm, minimum 3 
direct-current shocks 
without ROSC, 
received amiodarone 
300 mg, eligible 
for mechanical 
CPR, transfer time 
from scene to 
catheterization 
laboratory <30 min
232 NA 28/62 (45) NR NR
ALS indicates advanced life support; APACHE II, Acute Physiology, Age, Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disorder; CPR, 
cardiopulmonary resuscitation; ECPR, extracorporeal cardiopulmonary resuscitation; ED, emergency department; eGFR, estimated glomerular filtration rate; EMS, 
emergency medical services; IABP, intra-aortal balloon pump; ICU, intensive care unit; IHCA, in-hospital cardiac arrest; NA, not applicable; NR, not reported; OHCA, 
out-of-hospital cardiac arrest; OR, odds ratio; PCI, percutaneous coronary intervention; ROSC, return of spontaneous circulation; RR, relative risk; SOFA, sequential 
organ failure assessment; and TTM, targeted temperature management.
Table 7. Continued
Study, Year Country
Years of 
Patient 
Inclusion
IHCA vs 
OHCA Inclusion Criteria
Patients 
Analyzed, 
n
Covariates Included 
in Adjusted Analysis
Hospital Discharge/1 mo
Exposed, 
n (%)
Unexposed, 
n (%)
Adjusted 
Results, OR 
or RR (95% 
CI)
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Dispatcher Instruction in CPR:  
DA-CPR—Pediatrics
ILCOR commissioned an SR to identify and analyze all 
published evidence reporting outcomes of offering DA-
CPR for OHCA in infants and children.3 The Pediatric 
Life Support Task Force analyzed and discussed the SR 
and all of the studies identified by the SR, developed 
a draft CoSTR, and posted it online for public com-
ment.102 The draft CoSTR was visited 1736 times during 
the 2-week comment period. The task force reviewed 
the 2 posted comments; both endorsed the summary 
of science and treatment recommendation.
The emergency medical dispatcher is an essential 
link in the chain of survival. In addition to dispatching 
EMS resources to medical emergencies, EMS dispatch-
ers are increasingly being trained to recognize cardiac 
arrest, to assist bystanders in initiating resuscitation, 
and to support bystanders in optimizing resuscitation 
efforts. The international community is continuing to 
explore ways to increase bystander CPR for cardiac ar-
rests. One such strategy involves dispatchers providing 
CPR instruction to callers/bystanders: DA-CPR. For such 
a strategy to be successful, it requires the EMS system 
to be configured to support the dispatcher to offer 
DA-CPR and the bystander to deliver CPR with support 
from the dispatcher.
This COSTR explores the impact of DA-CPR on sur-
vival and neurological outcomes after OHCA in infants 
and children.
Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Infants and children with presumed cardiac 
arrest in out-of-hospital settings
Intervention: Patients/cases or EMS systems where 
DA-CPR is offered
Comparators: Studies with comparators where ei-
ther systems or specific cardiac arrest cases are not of-
fered dispatch-assisted CPR
Outcomes (critical outcomes included): Survival with 
favorable neurological function (at hospital discharge, 
1 month, or 6 months), survival (hospital discharge, 1 
month, or 1 year), short-term survival (ROSC, hospital 
admission), and provision of bystander CPR; impor-
tant outcomes were initial shockable rhythm and time 
to CPR
Study designs: RCTs and nonrandomized stud-
ies (non-RCTs, interrupted time series, controlled 
before-and-after studies, cohort studies) eligible for 
inclusion
Time frame: All years and all languages included 
with the last search performed July 1, 2018; ongoing 
or unpublished studies identified through a search of 
ClinicalTrials.gov online registry16
PROSPERO registration: CRD42018091427
Consensus on Science
Four studies were included in the SR comparing the 
outcomes for children with OHCA when bystanders 
were offered DA-CPR.25,26,39,103 All the studies were co-
hort studies of registry data: 2 from the same registry in 
Japan and 2 from the same registry in Korea. When the 
overlapping populations from the same source (regis-
try) were reported for the same outcome, the larger of 
the 2 studies was used in the analysis.26,39 The studies 
by Goto and colleagues26 and Chang and colleagues39 
included adjusted analyses.
There were 2 major groups for outcome compari-
sons:
• Those patients from systems that included DA-CPR 
compared with those from systems that offered 
no dispatcher CPR assistance; in 1 study, 25% 
of bystanders who were offered DA-CPR did not 
actually provide CPR.26
• Those patients who actually received DA-CPR com-
pared with those who did not receive DA-CPR; the 
group who did not receive DA-CPR was subdivided 
into those who received unassisted CPR and those 
who received no CPR.
Because all studies the task force evaluated were non-
randomized, any reported findings must be considered 
as occurring in association with the CPR (the interven-
tion) provided rather than as caused by it.
Cardiac Arrest Outcomes in EMS Systems With and 
Without DA-CPR
One study from the All-Japan Utstein Registry26 report-
ed neurological outcome at 1 month in a cohort of 
4306 infants and children with OHCA. There was no 
association in either adjusted or unadjusted analysis 
between favorable neurological outcome at 1 month 
and systems offering DA-CPR compared with such 
outcomes in systems not offering DA-CPR. The same 
study from Japan did not document any association 
between improved survival at 1 month and DA-CPR in 
the unadjusted analysis, but such an association was 
suggested in the adjusted analysis. In a separate analy-
sis, there was no association between the incidence of 
shockable pediatric arrest rhythms and systems offer-
ing DA-CPR.26
Three studies examined the delivery of bystander 
CPR in systems that offered DA-CPR compared with 
those that did not. In addition to the All-Japan study 
reported by Goto et al,26 2 studies25,31 included unad-
justed analysis of 3309 children with OHCA. These 
studies reported a significantly higher rate of CPR in 
the cohorts offered DA-CPR in both unadjusted and 
adjusted analyses. In addition, the Goto et al All-Ja-
pan study reported earlier time to CPR initiation as-
sociated with systems that offered DA-CPR compared 
with those that did not.26 Table 8 provides additional 
information.
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Cardiac Arrest Outcomes in Infants and Children With 
OHCA Who Received Bystander DA-CPR Compared 
With Those Who Received No CPR
Goto and colleagues26 and Chang and colleagues39 re-
ported the association of significantly improved neuro-
logical outcomes and DA-CPR compared with no CPR. 
In both unadjusted and adjusted data from the Goto et 
al series, there were significantly higher rates of favor-
able neurological outcome (CPC 1 and 2) at 1 month 
associated with those who received DA-CPR compared 
with those who received no CPR. There were also sig-
nificantly higher rates of survival to 1 month in the DA-
CPR cohort in both unadjusted and adjusted analyses.26 
In both adjusted and unadjusted analyses, the Chang 
et al observational study of 1661 children with OHCA 
reported an association between significantly improved 
likelihood of favorable neurological outcome at hos-
pital discharge and survival to hospital discharge and 
DA-CPR compared with no CPR.39 Table 9 gives further 
information.
In comparisons of infants and children receiving 
DA-CPR with those receiving unassisted bystander 
CPR, Goto et al26 reported lower rates of favorable 
neurological outcome and survival at 1 month in the 
DA-CPR group. Chang et al,39 however, found no dif-
ference in either survival or favorable outcome at dis-
charge between those receiving DA-CPR and those 
receiving unassisted bystander CPR. Chang et al re-
ported an increase in rates of sustained ROSC associ-
ated with DA-CPR compared with no CPR but docu-
mented no such increase when comparing those who 
received DA-CPR with those who received unassisted 
bystander CPR.39
Both the Goto et al26 and Chang et al39 studies 
examined the presence of a shockable rhythm as an 
outcome. The pooled data did not document an as-
sociation between an increased presence of shockable 
rhythm and receipt of DA-CPR compared with those 
who received no CPR, and there was a negative asso-
ciation when those receiving DA-CPR were compared 
with those receiving unassisted CPR.
Not surprisingly, Goto et al26 and Chang et al39 re-
ported an association between DA-CPR and shorter 
times to CPR initiation compared with the group with 
no bystander CPR. These 2 studies, however, reported 
that time to CPR initiation was longer in the DA-CPR 
than in the unassisted bystander CPR cohort. Table 10 
provides further information.
Treatment Recommendations
We recommend that EMS dispatch centers offer dis-
patch CPR instruction (DA-CPR) for presumed pediatric 
cardiac arrest (strong recommendation, very low cer-
tainty of evidence).
We recommend that emergency dispatchers provide 
CPR instruction for pediatric cardiac arrest when no 
bystander CPR is in progress (strong recommendation, 
very low certainty of evidence).
We cannot make a recommendation for or against 
emergency dispatch provision of CPR instructions for 
pediatric cardiac arrest when bystander CPR is already 
in progress (no recommendation, very low certainty of 
evidence).
Justification and Evidence to Decision  
Framework Highlights
This topic was prioritized by the Pediatric Life Sup-
port Task Force after publication of several new stud-
ies since the previous pediatric SR was published in 
2011. The 2011 review found limited evidence to sup-
port DA-CPR.104 In considering the importance of this 
topic, the Pediatric Life Support Task Force noted that 
bystander CPR significantly improves the likelihood of 
survival after OHCA, but bystander CPR rates remain 
very low.105
Table 8. Comparison of Outcomes of Infants and Children With OHCA in EMS Systems With and Without DA-CPR Programs (ie, DA-CPR Offered 
Versus Not Offered)
Outcomes (Importance)
Pediatric Participants
(Studies), n
Certainty 
of Evidence 
(GRADE) OR or RR (95% CI)* RD With DA-CPR and No DA-CPR
Survival with favorable neurological 
outcome at 1 mo (critical)
4306 (1 cohort study)26 Very low RR, 1.03 (0.73–1.46) 1 more per 1000 (8 fewer–14 more)
AOR, 1.45 (0.98–2.15); P=0.06
Survival to 1 mo (critical) 4306 (1 cohort study)26 Very low RR, 1.15 (0.95–1.40) 14 more per 1000 (4 fewer–35 more)
AOR, 1.46 (1.05–2.03); P=0.02
Delivery of bystander CPR (critical) 3309 (2 studies)25,31 Low RR, 2.25 (2.05–2.47) 315 more per 1000 (188–437 more)
4306 (1 cohort study)26 Moderate AOR, 7.51 (6.58–8.57); P<0.0001
Shockable initial rhythm (important) 4306 (1 cohort study)26 Very low RR, 0.82 (0.61–1.10) 8 fewer per 1000 (5–18 fewer)
Arrest to CPR initiation (important) 4306 (1 cohort study)26 Very low Shorter time to CPR: median, 4 (IQR, 1–9) min with DA-CPR vs 11 (IQR 
7–16) min; P<0.000
AOR indicates adjusted odds ratio; CPR, cardiopulmonary resuscitation; DA-CPR, dispatcher-assisted cardiopulmonary resuscitation; EMS, emergency medical 
services; GRADE, Grading of Recommendations, Assessment, Development, and Evaluation; IQR, interquartile range; OHCA, out-of-hospital cardiac arrest; OR, 
odds ratio; RD, risk difference; and RR, relative risk.
*RRs are presented for unadjusted analyses, and ORs are presented for adjusted analyses.
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Soar et al 2019 ILCOR CoSTR Summary
In developing the CoSTR, the Pediatric Life Support 
Task Force agreed that consideration of both unadjust-
ed and adjusted analyses was essential to adequately 
evaluate the published evidence. We recognize that 
unadjusted analysis might be confounded by tempo-
ral changes and systematic and patient care differences 
between and within EMS systems.
In making a strong recommendation for dispatch 
centers to offer DA-CPR despite very-low-certainty evi-
dence, the Pediatric Life Support Task Force considered 
Table 9. Comparison of Outcomes of Infants and Children With OHCA Who Received Bystander DA-CPR Compared With Those Who Received No CPR
Outcomes (Importance)
Participants
(Studies), n
Certainty 
of Evidence 
(GRADE) OR or RR (95% CI)* RD With DA-CPR and No CPR
Survival with favorable 
neurological outcome at 1 mo 
(critical)
4306
(1 cohort study)26
Very low RR, 1.47 (1.05–2.07) 12 more per 1000 (1–26 more)
AOR,1.81 (1.23–2.67); P=0.003
Survival with favorable 
neurological outcome at 
hospital discharge (critical)
1661
(1 cohort study)39
Low RR, 3.43 (2.10–5.59) 54 more per 1000 (25–99 more)
AOR, 2.22 (1.27–3.88); P=0.005
Survival at 1 mo (critical) 4306
(1 cohort study)26
Very low RR, 1.38 (1.15–1.65) 31 more per 1000 (12–53 more)
AOR, 1.63 (1.32–2.01); P<0.0001
Survival to hospital discharge 
(critical)
1661
(1 cohort study)39
Moderate RR, 2.87 (2.02–4.06) 84 more per 1000 (47–132 more)
Low AOR, 2.23 (1.47–3.38); P=0.002
Sustained ROSC (critical) 1661
(1 cohort study)39
Very low RR, 2.68 (1.94–3.70) 89 more per 1000 (51–137 more)
Shockable initial rhythm 
(important)
5967
(2 cohort studies)26,39
Very low RR, 1.52 (0.81–2.86) 26 more per 1000 (10 fewer–89 more)
Arrest to CPR initiation 
(important)
4306
(1 cohort study)26
Very low Shorter time with DA-CPR: median, 1 (IQR, 0–5) vs 11 (IQR, 7–15) min
1265
(1 cohort study)31
Shorter time with DA-CPR: median, 4 (IQR, 0–13) vs 10 (IQR, 6–18) min; P=0.01
AOR indicates adjusted odds ratio; CPR, cardiopulmonary resuscitation; DA-CPR, dispatcher-assisted cardiopulmonary resuscitation; GRADE, Grading of 
Recommendations, Assessment, Development, and Evaluation; IQR, interquartile range; OHCA, out-of-hospital cardiac arrest; OR, odds ratio; RD, risk difference; 
ROSC, return of spontaneous circulation; and RR, relative risk.
*RRs are presented for unadjusted analyses, and ORs are presented for adjusted analyses.
Table 10. Outcomes of Infants and Children With OHCA Who Received Bystander DA-CPR Compared With Those Who Received Unassisted 
Bystander CPR
Outcomes (Importance)
Participants
(Studies), n
Certainty of Evidence
(GRADE)
RR
(95% CI)*
RD With DA-CPR and  
Unassisted CPR
Survival with favorable 
neurological outcome at 1 
mo (critical)
2722
(1 cohort study)26
Very low 0.59 (0.41–0.84) 26 fewer per 1000 (9–37 fewer)
Survival with favorable 
neurological outcome at 
hospital discharge (critical)
970
(1 cohort study)39
Very low 0.97 (0.61–1.56) 2 fewer per 1000 (32 fewer–43 
more)
Survival at 1 mo (critical) 2722
(1 cohort study)26
Very low 0.77 (0.62–0.95) 34 fewer per 1000 (6–57 fewer)
Survival at hospital discharge 
(critical)
1661
(1 cohort study)39
Very low 0.99 (0.69–1.41) 2 fewer per 1000 (42 fewer–51 
more)
Sustained ROSC (critical) 1661
(1 cohort study)39
Very low 0.84 (0.62–1.16) 26 fewer per 1000 (26 more–66 
fewer)
Shockable initial rhythm 3692
(2 cohort studies)26,39
Very low 0.54 (0.35–0.82) 61 fewer per 1000 (31–83 fewer)
Arrest to CPR initiation 2722
(1 cohort study)26
Very low Longer time with DA-CPR: median, 4 (IQR, 0–13) vs 1 (IQR, 
0–5) min
766
(1 cohort study)31
Very low Longer time with DA-CPR: median, 4 (IQR, 0–13) vs 2 (IQR, 
0–10) min
CPR indicates cardiopulmonary resuscitation; DA-CPR, dispatcher-assisted cardiopulmonary resuscitation; GRADE, Grading of Recommendations, Assessment, 
Development, and Evaluation; IQR, interquartile range; OHCA, out-of-hospital cardiac arrest; RD, risk difference; ROSC, return of spontaneous circulation; and RR, 
relative risk.
*RRs are presented for unadjusted analyses.
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the benefit for the critical outcome of survival in the 
adjusted analyses and the large positive effect of in-
creased bystander CPR and reduced time to initiation 
of CPR when DA-CPR was offered. Implementation 
of DA-CPR appears to be acceptable and feasible, as 
many EMS systems have demonstrated. However, its 
cost-effectiveness and impact on health equity have 
not been evaluated and, until documented, may pres-
ent barriers to implementation in underresourced re-
gions. In addition, successful implementation of any 
program of DA-CPR requires a process of continuous 
quality improvement to ensure that dispatchers can 
quickly identify a likely cardiac arrest and assist the by-
stander in starting CPR in a very short time.106
In making a strong recommendation despite low-
certainty evidence, the task force valued the consisten-
cy of results indicating benefit for all critical and impor-
tant outcomes, with the exception of shockable rhythm 
(no benefit). This failure to demonstrate contributions 
of DA-CPR to improvement in likelihood of shockable 
initial rhythm aligns with the adult meta-analysis.3
In abstaining from recommending for or against 
DA-CPR when bystander CPR is already in progress, 
the task force noted the very-low-certainty evidence 
available, the consistency of inferior and neutral re-
sults for all of the critical outcomes, and the lack of 
any adjusted analyses for this group. The negative 
results associated with DA-CPR compared with unas-
sisted bystander CPR may have several potential ex-
planations: Bystander CPR was initiated earlier than 
DA-CPR because the bystander did not experience the 
delay resulting from calling a dispatcher and receiv-
ing instruction, or the bystanders who performed CPR 
and refused dispatch assistance were likely trained in 
CPR and may have provided a higher quality of CPR 
than that provided by the untrained bystander who 
required remote dispatch assistance. This particular 
finding suggests the potential benefits of widespread 
community-based CPR training.
Consideration of types of DA-CPR systems or inter-
ventions to improve the quality of DA-CPR was beyond 
the scope of this review. A limitation of the evidence 
that forms the basis of these treatment recommenda-
tions is that data are derived from only 2 countries: Ja-
pan and Korea. The EMS systems involved may differ in 
their response to OHCA compared with EMS systems 
and responses in other regions. Thus, caution is re-
quired in attempts to extrapolate these results to differ-
ent EMS systems of care.
Although this review did not address the content 
of CPR instructions, we elected to specify that CPR in-
structions should include rescue breaths for pediatric 
patients with cardiac arrest to be consistent with previ-
ous CoSTRs107 and to draw attention to this important 
distinction from adult CPR instructions.
Knowledge Gaps
The Pediatric Life Support Task Force identified several 
knowledge gaps requiring further investigation. The 
overall challenge is the need to determine whether 
dispatchers can effectively guide untrained bystand-
ers to provide effective conventional CPR for a child 
in cardiac arrest. To ensure that consistent analysis 
is included in all future studies of DA-CPR in chil-
dren, we recommend the research include/address 
the following:
• Optimal dispatcher training (and retraining) in 
recognizing OHCA and in providing DA-CPR for 
children
• Identification of the specific scripted language 
used by dispatchers and its effects on the initiation 
of bystander CPR
• Indication of how CPR instructions are provided 
(by the phrasing and enunciation of words, video 
adjuncts via cellphone, etc)
• Report of the certainty of bystander CPR (includ-
ing the time required for identification of cardiac 
arrest, time to initiation of CPR, and whether con-
ventional CPR or chest compression–only CPR was 
given)
• Inclusion of subsequent in-hospital (postarrest) 
factors
• Indication of specific dispatcher guidance provided 
(eg, to pace the compression rate) when bystander 
CPR is already initiated
• EMS response times
• Analysis of the cost-effectiveness of DA-CPR
• Content of CPR/DA-CPR instructions, specifically 
addressing the role of ventilation in infant and 
child CPR
• Report of long-term outcomes, including QOL 
outcomes
• Adjustment for variables such as bystander CPR 
characteristics, patient, age, sex, and previous 
bystander CPR training
Advanced Airway Interventions in 
Pediatric Cardiac Arrest
The management of the airway is central in pediatric 
resuscitation, particularly because respiratory condi-
tions are a frequent cause of pediatric cardiac arrest. 
Placement of an advanced airway device such as an 
SGA or TI may allow more effective resuscitation than 
the alternative of BMV. However, uncertainties remain 
about the risk and benefit of each method of man-
aging the airway during CPR. Persistent challenges 
surround issues of the provision of effective (but not 
excessive) ventilation; delivery of continuous chest 
compressions; and risks of failed intubation attempts, 
unrecognized esophageal intubation, prolonged inter-
ruptions in chest compressions, and inadvertent exces-
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sive ventilation. These issues can affect the quality of 
resuscitation.
ILCOR commissioned an SR to identify and analyze 
all published evidence reporting outcomes of advanced 
airway placement during CPR in infants and children 
during OHCA and IHCA.7 The Pediatric Task Force ana-
lyzed and discussed the SR and all of the studies identi-
fied by the SR, developed a draft CoSTR, and posted 
it online for public comment.108 The draft CoSTR was 
viewed 341 times during the 2-week comment period. 
The 4 posted comments endorsed the CoSTR, and all 
acknowledged the complexity of the issues surrounding 
use of an advanced airway during pediatric resuscitation 
and the need for adequate training in all techniques.
Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Infants and children in any setting (in hos-
pital or out of hospital) who have received chest com-
pressions or a defibrillation dose on whom CPR is being 
performed
Intervention: Placement of an advanced airway device
Comparators: Primary—BMV alone or with non–
advanced airway interventions; secondary—another 
advanced airway device
Outcomes: Any clinical outcome
Study designs: RCTs and nonrandomized studies 
(non-RCTs, interrupted time series, controlled before-
and-after studies, cohort studies) of pediatric patients 
eligible for inclusion; if insufficient studies available 
from which to draw a conclusion, case series of ≥4 may 
be included; case reports, unpublished studies, and 
nonhuman studies excluded
Time frame: All years and all languages included (as 
long as there is an English abstract); unpublished stud-
ies (eg, conference abstracts, trial protocols) excluded; 
the last search was performed on September 24, 2018
PROSPERO registration: CRD42018102430
Consensus on Science
The task force reviewed the evidence of outcomes 
with the following comparisons: TI with BMV, SGA 
with BMV, and TI with SGA during pediatric cardiac 
arrest. Detailed information from all studies reviewed 
is summarized in Table 11. Summative results from 8 
of the studies are included in Table 12, which excluded 
cohort studies with results too heterogeneous to en-
able meta-analysis.
Studies Comparing TI With BMV Alone
Fourteen studies were included in the SR comparing TI 
with BMV, including 1 clinical trial109 and 13 observa-
tional studies.110–122
Although the clinical trial was excellent in design and 
execution, it was downgraded to low certainty as a re-
sult of indirectness. The study was conducted in 1994 
to 1996, before more recent revisions in resuscitation 
guidelines that emphasize minimally interrupted chest 
compressions as part of high-quality CPR. This study as-
signed 591 children with OHCA to TI or BMV on an 
odd- and even-day basis. The use of TI resulted in no 
difference in likelihood of survival with the critical out-
come of favorable neurological function or survival to 
hospital discharge.109
The 13 identified observational studies provided 
evidence of very low or low certainty. Three of these 
observational studies110–112 used propensity matching 
to attempt to control for factors driving the decision 
to intubate. However, a limitation of all 3 studies was 
the failure to distinguish patients with unsuccessful at-
tempts at advanced airway placement from those who 
were managed with BMV alone. When combined, 
these studies found a reduced likelihood of survival 
with favorable neurological function or survival to hos-
pital discharge associated with TI.110–112 The other 10 
observational studies found no statistically significant 
association between TI and these outcomes.113–120,122,124
Studies Comparing SGA With BMV Alone
The 4 observational studies comparing SGA with BMV 
provided very-low-certainty evidence. Two studies used 
propensity matching to reduce bias, but both had the 
limitation of failure to distinguish between patients 
who had unsuccessful attempts at SGA insertion and 
those who were managed with BMV without attempt-
ed SGA insertion.111,112 Two other observational stud-
ies reported only unadjusted data.113,120 None of these 
studies found a significant association between SGA 
use and survival with favorable neurological function or 
survival to hospital discharge.
Studies Comparing TI With SGA
The evidence comparing TI with SGA during pediat-
ric resuscitation comes from 4 observational studies 
of OHCA111–113,120; 2 of these  studies used propensity 
matching.111,112 When combined, neither the propensity-
matched studies111,112 nor the unadjusted cohort stud-
ies113,120 found a significant association between the 
choice of advanced airway and survival with favorable 
neurological function or survival to hospital discharge.
Treatment Recommendations
We suggest the use of BMV rather than TI or SGA in 
the management of children during cardiac arrest in the 
out-of-hospital setting (weak recommendation, very 
low certainty of evidence).
There is insufficient evidence to support any recom-
mendation about the use of TI or SGA in the manage-
ment of children with cardiac arrest in the in-hospital 
setting.
Justification and Evidence to Decision  
Framework Highlights
Advanced airway interventions have been long-established 
components of the advanced life support bundle of care 
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in adults and children. As a result of inherent limitations 
in their design and data sources, the available studies pro-
vide only very-low-certainty evidence about whether at-
tempting advanced airway placement during resuscitation 
(ie, before ROSC) improves resuscitation outcomes. The 
best available data show no benefit from advanced airway 
interventions, and some suggested association with harm 
for the critical outcomes of survival with favorable neu-
rological outcome and survival to hospital discharge. The 
effects of placement of an advanced airway are uncertain 
for the short-term resuscitation outcomes of survival to 
hospital admission and ROSC. Although these short-term 
outcomes do not ultimately benefit the patient, they may 
benefit the family.
Table 11. Pediatric Studies Comparing Use of BMV With Advanced Airways During Cardiac Arrest
Study
Years 
Conducted Setting Location
Patients/Total Treated, n (%)
Survival With Good Neurological Function Survival to Hospital Discharge
TI BMV SGA TI BMV SGA
Clinical trials
  Gausche et 
al,109 2000
1994–1997 OHCA United States 10/290 (3.4) 15/301 (5.0) … 24/290 (8.3) 24/301 (8.0) …
Observational studies with propensity matching
  Andersen et 
al,110 2016
2000–2014 IHCA United States 185/987 (18.7) 211/983 (21.4) … 411/1135 (36.2) 460/1135 (40.7) …
  Hansen et 
al,111 2017
2013–2015 OHCA United States 34/727 (4.7) 89/781 (11.4) 13/215 (6.0) 51/727 (7.0) 110/781 (14.1) 22/215 (10.2)
  Ohashi-
Fukuda et 
al,112 2017
2011–2012 OHCA Japan 0/31 (0.0) 16/346 (4.6) 12/315 (3.8) 4/31 (12.9) 37/346 (11.0) 47/315 (14.9)
Simple observational studies
  Abe et al,113 
2012
2005–2008 OHCA Japan … … … 12/185 (6.5) 243/2734 (8.9) 9/270 (3.3)
  Aijian et 
al,114 1989
1984–1987 OHCA United States … … … 1/28 (3.6) 1/14 (7.1) …
  Deasy et 
al,115 2010
1999–2007 OHCA Australia … … … 13/154 (7.8) 2/26 (7.7) …
  Del Castillo 
et al,116 
2015
2007–2009 IHCA Argentina, 
Brazil, 
Columbia, 
Chile, Ecuador 
Honduras, 
Italy, Paraguay, 
Portugal, Spain
44/71 (71.0) 43/53 (81.1) … … … …
  Guay and 
Lorti,117 2004
1983–1987 IHCA Canada … … … 20/90 (22.2) 30/55 (54.5) …
  Pitetti et 
al,118 2002
1995–1999 OHCA United States … … … 5/150 (3.3) 0/39 (0.0) …
  Sirbaugh et 
al,119 1999
1992–1995 OHCA United States 5/229 (2.2) 0/26 (0.0) … 6/229 (2.6) 0/26 (0.0) …
  Tham et 
al,120 2018
2009–2012 OHCA Japan, Korea, 
Malaysia, 
Singapore, 
Taiwan, 
Thailand, 
United Arab 
Emirates
3/18 (16.7) 29/791 (3.7) 3/109 (2.8) 3/18 (16.7) 68/791 (8.6) 9/109 (8.3)
Simple observational studies without raw data (analyzed separately from meta-analysis)
  Fink et al,121 
2016
2007–2012 OHCA United States … … … AOR, 0.64 (95% CI, 0.37–1.13) 
favoring BMV over AAW*
…
  Tijssen et 
al,122 2015
2005–2012 OHCA Canada, 
United States
… … … AOR, 0.69 (95% CI, 0.43–1.10) 
favoring BMV over AAW†
…
AAW indicates advanced airway; AOR, adjusted odds ratio; BMV, bag-mask ventilation; IHCA, in-hospital cardiac arrest; OHCA, out-of-hospital cardiac arrest; 
SGA, supraglottic airway; and TI, tracheal intubation.
*In the study by Fink et al,121 92% of AAW attempts were TI attempts.
†In the study by Tijssen et al,122 93% of AAW attempts were TI attempts.
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Effective BMV, TI, and insertion of an SGA are all 
difficult skills that require good initial training, re-
training, and quality control to be performed con-
sistently, safely, and effectively. To be effective, pedi-
atric advanced airway programs require a moderate 
investment in equipment and a significant invest-
Table 12. Summative Results of Studies Used in the Pediatric Airway Systematic Review for Each Comparison and Grouped by Outcome
Outcomes (Importance) Participants (Studies), n
Certainty 
of Evidence 
(GRADE)
RR
(95% CI)
Absolute 
Risk With 
Comparator ARD With Intervention
TI (I) vs BMV (C)*
  Survival, favorable 
neurological outcome (critical)
591 (1 RCT)109 Low 0.69 (0.32–1.52) 50/1000 15 fewer per 1000 (48 fewer–17 more)
 3855 (3 propensity-matched 
observational)110–112
Very low † 150/1000 49 fewer per 1000 (77–21 fewer)
  Survival to hospital 
discharge (critical)
591 (1 RCT)109 Low 1.04 (0.6–1.79) 80/1000 3 more per 1000 (41 fewer–47 more)
 4155 (3 propensity-matched 
observational)110–112
Very low ‡ 268/1000 53 fewer per 1000 (20–87 fewer)
 3992 (2 observational 
studies)121,122
Very low ‡ Fink et al121: AOR, 0.64 (0.37–1.13)
Tijssen et al122: AOR, 0.69 (0.43–1.1)
  Survival to hospital 
admission (important)
1508 (1 propensity-matched 
observational)111
Very low 0.99 (0.83–1.17) 257/1000 3 fewer per 1000 (47 fewer–41 more)
 ROSC (important) 4155 (3 propensity-matched 
observational)110–112
Very low ‡ 417/1000 12 more per 1000 (15 fewer–39 more)
SGA (I) vs BMV (C)*
  Survival, favorable 
neurological outcome (critical)
1657 (2 propensity-matched 
observational)111,112
Very low † 93/1000 29 fewer per 1000 (75–fewer to 17 more)
 900 (1 nonadjusted 
observational study)120
Very low 0.75 (0.23–2.42) 37/1000 9 fewer per 1000 (43 fewer–24 more)
  Survival to hospital 
discharge (critical)
3904 (2 observational 
studies)113,120
Very low † 88/1000 35 fewer per 1000 (88 fewer–18 more)
  Survival to hospital 
admission (important)
996 (1 propensity-matched 
observational)111
Very low 1.25 (0.99–1.57) 257/1000 64 more per 1000 (6 fewer–133 more)
 900 (1 observational study)120 Very low 0.85 (0.44–1.87) 97/1000 15 fewer per 1000 (70 fewer–41 more)
 ROSC (important) 900 (1 observational study)120 Very low 1.26 (0.82–1.92) 171/1000 40 more per 1000 (41 fewer–121 more)
TI (I) vs SGA (C)*
  Survival, favorable 
neurological outcome (critical)
1288 (2 propensity-matched 
observational)111,112
Very low † 47/1000 22 fewer per 1000 (51 fewer–6 more)
 127 (1 nonadjusted 
observational study)120
Very low 6.06 (1.32–27.7) 28/1000 139 more per 1000 (36 fewer–314 more)
  Survival to hospital 
discharge (critical)
1288 (2 propensity-matched 
observational)111,112
Very low † 130/1000 31 fewer per 1000 (73 fewer–11 more)
 582 (2 observational 
studies)113,120
Very low † 47/1000 34 more per 1000 (6 fewer–75 more)
  Survival to hospital 
admission (important)
942 (1 propensity-matched 
observational)111
Very low 0.79 (0.63–1.0) 321/1000 67 fewer per 1000 (136 fewer–4 more)
 127 (1 observational study)120 Very low 4.33 (2.28–8.2) 128/1000 472 more per 1000 (198–665 more)
  ROSC (important) 1288 (2 propensity-matched 
observational)111,112
Very low † 162/1000 26 fewer per 1000 (129 fewer–78 more)
 127 (1 observational study)120 Very low 3.42 (2.16–5.44) 211/1000 511 more per 1000 (291–732 more)
AOR indicates adjusted odds ratio; ARD, absolute risk difference; BMV, bag-mask ventilation; C, comparator; GRADE, Grading of Recommendations, 
Assessment, Development, and Evaluation; I, intervention; RCT, randomized controlled trial; ROSC, return of spontaneous circulation; RR, relative risk; SGA, 
supraglottic airway; and TI, tracheal intubation.
Summative results of studies used in the systematic review are shown for each comparison and grouped by outcome.
*Cohort studies, amenable to meta-analysis, were not reported in this table if they produced results that were too heterogeneous (I2 index >75%). Studies 
included in this table were therefore 1 clinical trial,109 3 propensity-matched observational studies,110–112 and 4 nonadjusted observational studies.113,120–122
†To minimize ambiguity, RR calculations were reported only for single studies, not for meta-analyses. RR calculations were considered less informative and 
sometimes produced divergent results, likely a consequence of zero-numerator cells.123
‡The first 2 studies121,122 provided retrospective cohort data in adjusted form only (AOR), not amenable to meta-analysis.
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ment in training, skills maintenance, and quality con-
trol programs.
The benefit or harm associated with advanced air-
way–based resuscitation may differ across settings. The 
available data do not inform the questions of whether 
better outcomes might be achieved by advanced air-
way–based strategies by highly trained and experienced 
airway operators, during long distance transport, or in 
prolonged resuscitation situations. The analyzed data 
are relevant only to advanced airway interventions dur-
ing CPR and do not pertain to airway management af-
ter ROSC or in other critical situations.
Knowledge Gaps
This evidence evaluation did not identify any clinical 
trials addressing airway management during cardiac 
arrest in the in-hospital setting, and future studies are 
needed to address this knowledge gap. In addition, the 
only randomized clinical trial undertaken in the out-of-
hospital setting109 was performed before major chang-
es in resuscitation guidelines; future studies are needed 
in the out-of-hospital setting. The task force identified 
several additional knowledge gaps requiring further in-
vestigation:
• Prehospital, emergency department–based, and 
in-hospital studies of similar design comparing TI, 
SGA, and BMV with planned subgroup analyses 
based on patient age and cause of arrest
• Studies of advanced airway use in specific contexts 
such as long-distance transport and prolonged 
resuscitation situations in the hands of highly 
trained and experienced airway operators; we 
have no knowledge about these subgroups, which 
are likely to be important
ECPR: Infants and Children
ECPR has been used with increasing frequency as 
rescue therapy for refractory cardiac arrest. In pediat-
rics, ECPR is used most frequently after postoperative 
IHCA associated with congenital heart disease and 
progression of low cardiac output or arrhythmias, al-
though there are recent reports of applications for 
cardiac arrest from other causes. This topic was last 
reviewed by the Pediatric Life Support Task Force in 
2015.125
ILCOR commissioned an SR to identify and analyze 
all published evidence reporting outcomes of ECPR in 
infants, children, and adults after OHCA and IHCA.6 
The Pediatric Life Support Task Force analyzed and dis-
cussed the SR and all of the pediatric studies identi-
fied by the SR, developed a draft CoSTR, and posted it 
online for public comment.126 The draft document was 
viewed 264 times during the 2-week comment period. 
The task force reviewed the single posted comment, 
which endorsed the CoSTR.
Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Adults (age ≥18 years) and children (age 
<18 years) with cardiac arrest in any setting (out of hos-
pital or in hospital)
Intervention: ECPR, including ECMO or cardiopul-
monary bypass, during cardiac arrest
Comparator: Manual and/or mechanical CPR
Outcomes: Clinical outcomes, including short-term 
survival and neurological outcomes (eg, hospital dis-
charge, 28 days, 30 days, and 1 month) and long-term 
survival and neurological outcomes (eg, 3 months, 6 
months, and 1 year)
Study design: Randomized trials, non-RCTs, and 
observational studies (cohort studies and case-control 
studies) with a control group included; animal studies, 
ecological studies, case series, case reports, reviews, ab-
stracts, editorials, comments, and letters to the editor 
not included
Time frame: All years and all languages included (as 
long as there was an English abstract); unpublished 
studies, published abstracts (eg, conference abstracts), 
and trial protocols excluded; literature search conduct-
ed on December 19, 2017, and updated May 22, 2018
PROSPERO registration: CRD42018085404
Note: Information about outcomes of ECPR use in 
adults is addressed elsewhere in this article (see ECPR 
for Cardiac Arrest: Adults).
Consensus on Science
In-Hospital Cardiac Arrest
For the critical outcomes of favorable longer-term neu-
rological outcome or of longer-term survival, no pediat-
ric studies were identified.
For the critical outcome of favorable neurological 
outcome at hospital discharge, we identified very-low-
certainty evidence (downgraded for very serious risk of 
bias) from 1 observational study; this study associated 
improved outcomes with ECPR compared with conven-
tional CPR (conditional logistic analysis adjusted odds 
ratio [AOR], 2.64 [95% CI, 1.91–3.67]; propensity anal-
ysis AOR, 1.78 [95% CI, 1.31–2.41]).127
For the critical outcome of survival to hospital discharge, 
we identified very-low-certainty evidence (downgraded 
for very serious risk of bias and inconsistency) from 3 stud-
ies with pediatric populations. Two studies associated im-
proved survival with ECPR compared with conventional 
CPR (AOR, 2.76 [95% CI, 2.08–3.66]127; AOR, 3.80 [95% 
CI, 1.40–10.32] in medical cardiac patients; and AOR, 
2.50 [95% CI, 1.3–4.81] in surgical cardiac patients).128
Out-of-Hospital Cardiac Arrest
No studies were identified that addressed this question.
Treatment Recommendations
We suggest that ECPR may be considered as an inter-
vention for selected infants and children (eg, cardiac 
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populations) with IHCA refractory to conventional CPR 
in settings where resuscitation systems allow ECPR to 
be well performed and implemented (weak recommen-
dation, very low certainty of evidence).
There is insufficient evidence in pediatric OHCA to 
formulate a recommendation for the use of ECPR.
Justification and Evidence to Decision Framework 
Highlights
In making a weak recommendation about the use of 
ECPR for pediatric IHCA, we recognize that despite a 
lack of comparative prospective studies identified in 
infants and children, patients with IHCA refractory to 
conventional CPR have a high probability of death un-
less therapies such as ECPR are used.
Providers should carefully consider the fact that the 
pediatric ECPR studies from which these recommenda-
tions are drawn consist predominantly of children with 
cardiac disease. This population may not adequately 
represent the local population for which guidelines 
may be implemented, so regional resuscitation councils 
must consider how generalizable the evidence can be 
to their regional systems of care.
The results of ECPR studies conducted in adults 
cannot be extrapolated to pediatric OHCA given 
the difference in causes of cardiac arrest between 
children and adults, the techniques and equipment 
applied for ECPR, and the post–cardiac arrest care 
interventions.
As noted, ECPR has been studied in very selected 
populations (eg, cardiac surgical or cardiac medical) and 
more rarely for pediatric cardiac arrest in general (ie, 
across all diseases and in all hospital settings).127 In ad-
dition, it has been used in organizations with a strong 
institution-based commitment to sustaining a resuscita-
tion system that includes ECPR with appropriate quality 
improvement systems.129,130 Such improvement systems 
include ongoing internal audits and iterative evaluation 
of performance and outcomes.129–133 As a result, these 
findings may not be broadly generalizable to other or-
ganizations.
ECPR is a complex resuscitation intervention that 
requires long-term commitment to sustain the exper-
tise, resources, training, and systems to provide support 
for patients and their families. Delivering this complex 
intervention involves added up-front investment and 
costs.134,135
The healthcare resources necessary to provide 
high-quality pediatric ECPR are likely to limit its broad 
adoption.
Knowledge Gaps
No published randomized trials have compared the 
outcomes of ECPR and conventional CPR in infants 
and children. Because some high-volume organiza-
tions have adopted ECPR for selected pediatric popu-
lations, this comparison may not be perceived as hav-
ing sufficient equipoise to allow randomization. As 
a result, alternative comparative study designs may 
be necessary to conduct clinical trials to study the 
following:
• Comparison of the probability of survival between 
ECPR and conventional CPR in IHCA
• Comparison of the likelihood of favorable neuro-
logical and functional outcome between ECPR and 
conventional CPR in IHCA
The timing and type of cannulation strategy for optimal 
transition from conventional CPR to ECPR remain to be 
studied to optimize neuro-CPR outcomes. The Pediatric 
Life Support Task Force identified the following unre-
solved issues:
• Optimal timing for ECPR cannulation during con-
ventional CPR
• Conditions (eg, pulmonary blood flow obstruction) 
for which ECPR, rather than conventional CPR, 
should be considered earlier in the resuscitation 
attempt
• Type and anatomic approach for cannulation for 
ECPR that allows best cerebral-CPR
• Identification of other technical aspects of ECPR 
that enable optimal cerebral-CPR, including ideal 
temperature management strategy, best circuit 
prime solution (reconstituted whole blood ver-
sus crystalloid), optimal fraction of device oxy-
genation to be delivered by the membrane lung, 
target oxygenation and decarboxylation to be 
delivered during ECPR, and the inotrope or vaso-
active medications delivered during ECPR that 
will optimize neurological and cardiopulmonary 
outcomes
The post–cardiac arrest care strategies after cannulation 
for ECPR remain to be studied, including how post–
cardiac arrest care therapies should be adapted in the 
context of ongoing ECPR.
There is an important gap in comparative studies of 
resuscitation for OHCA in special circumstances such 
as submersion or drowning, deep hypothermia or cold 
environment, respiratory arrest, or in the context of 
trauma. The Pediatric Life Support Task Force identified 
the following challenges for studies of ECPR for pediat-
ric OHCA in special circumstances:
• Identification of ideal select populations and cir-
cumstances to be considered for initial studies of 
ECPR for OHCA: Should these include children 
with cold-water drowning, people in an avalanche, 
or individuals with cold exposure?
• Optimal timing for initiation of ECPR: Should it 
be initiated at the scene of the arrest (ie, cannula-
tion in the field) or immediately on arrival at the 
hospital?
There are no published comparative studies on longer-
term functional outcomes or QOL outcomes in pediatric 
patients and in their families and caregivers after ECPR. 
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The Pediatric Life Support Task Force identified the fol-
lowing issues to be addressed:
• How longer-term functional and QOL outcomes 
compare between ECPR and conventional CPR 
for the pediatric population and their families and 
caregivers
• How bereavement outcomes compare between 
families and caregivers of nonsurvivors of cardiac 
arrest with ECPR compared with outcomes of 
families and caregivers of nonsurvivors of conven-
tional CPR
Whereas the cost-effectiveness of ECMO has been 
addressed in pediatric and adult publications, the 
cost-effectiveness of ECPR versus conventional CPR in 
pediatric cardiac arrest populations is not known and 
should be studied.
TTM After Cardiac Arrest
The last ILCOR Pediatric Life Support CoSTR review 
of pediatric TTM was published in 2015.125 Since that 
review, additional studies of pediatric TTM have been 
published, particularly in the in-hospital target popula-
tion. ILCOR commissioned an SR to identify and analyze 
all published evidence reporting outcomes of TTM in 
children who achieved ROSC after OHCA and IHCA.8 
The Pediatric Life Support Task Force analyzed and dis-
cussed the SR and all of the studies identified by that re-
view, developed a draft CoSTR, and posted it online for 
public comment.136 In response to the 2 posted com-
ments, the task force included additional information 
in the Justification and Evidence to Decision Framework 
Highlights section.
Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Pediatric patients (age >24 hours–18 years) 
who achieved ROSC after OHCA or IHCA
Intervention: TTM with a target temperature of 32°C 
to 36°C
Comparators: No TTM or TTM at an alternative tar-
get temperature range
Outcomes:
• Critical: favorable neurological outcome (good 
behavioral survival) at 1 year such as Pediatric CPC 
1 or 2137 and Vineland Adaptive Behavior Scales 
(Vineland-II) ≥70.138
• Important: favorable neurological outcome (at 
other time intervals), overall survival, and health-
related QOL at 3 time intervals: long term (1–3 
years), intermediate term (3–6 months), and short 
term (28–30 days or hospital discharge)
– Health-related QOL was defined with the 
use of pediatric-specific QOL tools (eg, the 
Pediatric QOL Inventory,139 the Infant Toddler 
QOL Questionnaire,140 or equivalent). Potential 
in-hospital adverse outcomes were also cap-
tured, including infection (culture proven), 
recurrent cardiac arrest, serious bleeding (red 
blood cell transfusion), and any arrhythmias (not 
leading to cardiac arrest).
Study designs: RCTs, quasi-RCTs (qRCTs), and non-
randomized cohort studies eligible to be included; ani-
mal studies, unpublished studies, published abstracts 
(eg, conference abstracts), and case series excluded
Time frame: All years to December 13, 2018
Languages: All languages included (if English ab-
stract was available)
A priori subgroups to be examined: Location of car-
diac arrest (in hospital and out of hospital), age groups, 
presumed type of cardiac arrest (cardiac, asphyxial, oth-
er), and use of ECMO
PROSPERO registration: CRD42018108441
Consensus on Science
The review identified 2 RCTs141,142 with moderate clinical 
heterogeneity (different settings), low methodological 
heterogeneity (same methods and in-hospital manage-
ment), and low or moderate statistical heterogeneity, 
allowing pooling of the results in the meta-analyses and 
separate subgroup analyses. The 2 RCTs were down-
graded to low certainty of effect as a result of inconsis-
tency and imprecision. Because only 2 relatively small 
RCTs were available, observational comparative data 
were considered, but we did not combine the RCT and 
non-RCT data. The observational studies that reported 
adequately adjusted results were pooled, whereas un-
adjusted results are shown, when relevant, without 
pooling (Table 13).
Favorable Neurobehavioral Survival
For the primary outcome of long-term favorable neu-
rological outcome (1 year), a pooled analysis of the 2 
RCTs (low certainty of evidence) found no statistically 
significant benefit of TTM 32°C to 34°C compared with 
TTM 36°C to 37.5°C.141,142 Two adjusted cohort stud-
ies reported no statistically significant benefit in either 
intermediate-term149 or short-term favorable neurologi-
cal outcome associated with use of TTM 32°C to 34°C 
compared with TTM 36°C to 37.5°C.143
Survival
For the secondary outcome of overall survival, a pooled 
analysis of the 2 RCTs (very low certainty of effect, 
downgraded for inconsistency and imprecision) found 
no statistically significant benefit in either long-term 
or short-term survival of TTM 32°C to 34°C compared 
with TTM 36°C to 37.5°C.141,142 One retrospective co-
hort study found no benefit in adjusted intermediate-
term survival associated with TTM 32°C to 34°C ver-
sus TTM 36°C to 37.5°C.149 Three cohort studies also 
reported no associated increase in adjusted short-term 
D
ow
nloaded from
 http://ahajournals.org by on February 25, 2020
December 10, 2019 Circulation. 2019;140:e826–e880. DOI: 10.1161/CIR.0000000000000734e850
CL
IN
IC
AL
 S
TA
TE
M
EN
TS
  
AN
D 
GU
ID
EL
IN
ES
Soar et al 2019 ILCOR CoSTR Summary
Table 13. Pediatric TTM in Children With OHCA Who Are Comatose After ROSC: Summary of Studies and Findings
Study, Year
Study Type; 
Years Enrolled n
Enrollment
Criteria
GCS/
Neurological
Target 
Temperature
Intervention
Temperature 
Comparison
Control
TTM
Duration Outcomes Comments
Chang et al,143 
2016
Retrospective 
review of 
national OHCA 
database; 
nonrandomized; 
January 1, 
2008–December 
31, 2014
663 Total,
81 TTM;
stratified by 
shockable vs 
nonshockable 
presenting 
rhythm
OHCA surviving 
to hospital 
admission 
(excluding deaths 
in ED, alert 
status after ED 
resuscitation, 
or unknown 
neurological 
status at 
discharge)
Not specified 32°C–34°C
based on 
intention to 
treat regardless 
of achieved 
temperature or 
duration; actual 
temperature 
measures not 
included; no 
standard care 
protocol
No standard 
care protocol; 
temperature 
measures not 
included
Minimum 12 h No difference in survival 
to hospital discharge 
between TTM (48.1%) 
and control (40.2%);
no difference in 
good neurological 
recovery (CPC 1 or 2 
at discharge) between 
TTM (22.2%) and 
control (18.7%);
no difference in effect of 
TTM between shockable 
and nonshockable 
presenting rhythm 
groups
Very low 
certainty 
resulting 
from lack of 
temperature 
data and 
nonrandomized 
treatment 
allocation
Cheng et al,144 
2018
Retrospective; 
historic and 
concurrent; 
controls
2013–2015; 
included 
neonates 
(23%–33%)
81 Events in 
75 patients; 
IHCA
CHD+CPR >5 
min or ECPR
(excluded 
intracranial 
hemorrhage)
Not specified Mean, 
33.6±0.2°C; 0 
had fever;
4/30 had
temperature 
<32°C;
TTM reached in 
1.4 h (median)
Mean, 
34.7±0.8°C; 
2/51 had fever; 
12/51 had 
temperature 
<32°C; TTM 
reached in 1.4 
h (median)
<1 y=72 
h (actual 
median: 63.1 
h), ≥1 y=48 
h (actual 
median: 45.9 h);
14/30 TTM 
patients 
rewarmed early
Survival:
Control, 59.1%; 
TTM, 61.5%;
no significant 
difference in survival 
or LOS;
follow-up to 26.5 mo; 
fewer patients with 
TTM had seizures 
(significant)
Control group 
included 
more patients 
with single 
ventricles and 
had low mean 
temperature 
with nearly 
half with 
temperature 
<32°C
Fink et al,124
2010
Retrospective 
cohort; patients 
with TTM after 
2002
181 Total,
40 TTM;
OHCA and 
IHCA
Admission to 
ICU with ROSC 
after cardiac 
arrest (even brief) 
who remained 
comatose after 
ROSC (excluded 
CHD, respiratory 
arrest no ROSC, 
brain death 
before arrest)
Consistent 
with AHA 
comatose; 
specific 
neurological 
criteria not 
reported
33.5°C–34.8°C;
mean, 
34.1±0.8°C;
reached in 
2.7±4.5 h
(mean, 0–4 
h); 18% had 
fever, 15% had 
temperature 
<32°C 
(associated with 
higher mortality)
Standard
33.6°C–
36.3°C; mean, 
31.6±19.5 h;
38% had fever 
in first 4 d
24 h (range 
16–48 h); 60% 
of patients 
with TTM 
presented at or 
below target 
temperature, 
so some 
were warmed 
to target 
temperature)
55% Survival with 
no difference 
between TTM and 
control; those with 
<36°C or >38°C 
on admission had 
significantly higher 
mortality than those 
with temperature 
36°C–38°C;
temperature <32°C in 
15% and associated 
with higher mortality;
no difference in 
hospital mortality, LOS
 
Lin et al,145
2013
Retrospective 
chart review;
January 1, 
2010–June 30, 
2012
43 Total,
15 TTM;
both OHCA 
and IHCA
At least 3 min of 
compression; only 
those surviving 
12 h included; 
CHD excluded
TTM GCS 
mean score 
4.67±1.94;
control GCS 
score
5±2.35
33.5±0.5°C 39% Needed 
active 
rewarming to 
normothermia
24–72 h 57% Overall survival; 
higher (78.6%) in 
TTM group vs 46.4% 
in control group 
(significant)
Some internal 
inconsistencies 
in numbers 
throughout 
article
Lin et al,146 
2018
Retrospective 
cohort 2010–
2017
64 Total;
25 TTM, all 
asphyxial
OHCA
CPR at least 3 min 
and survival at least 
12 h;
excluded 45 
children, including 
10 who died within 
12 h, 10 not in 
coma after ROSC, 
8 with preexisting 
neurological 
disease, and 8 
with TBI
GCS score 
≤8;
TTM GCS 
score 
3.4±1.04; 
control 
GCS score 
3.2±0.76
33°C within 6 h 
of arrest
35.5°C–
37.5°C;
56.4% 
needed active 
warming;
12.8% needed 
treatment for 
temperature 
>37.5°C
72 h Overall 1-mo survival, 
42.2%;
1-mo survival 
significantly higher in 
TTM (60%) vs control 
(30.8%) group;
TTM group had 
significantly better 
neurological 
outcomes; TTM group 
had longer LOS
 
Moler et al,142 
2015
International, 
multi-
institutional 
prospective RCT 
(September 1, 
2009–December 
31, 2012)
74 With 
OHCA 
drowning ≥2 
min of CC, 
remained 
comatose 
(GCS motor 
score 3 or 4) 
and ventilator 
dependent 
after ROSC;
46 randomized 
to TTM group
48 h to <18 y of 
age; excluded 
if GCS motor 
score 5 or 6, 
major trauma, 
inability to 
randomize within 
6 h, decision 
to withhold 
aggressive 
treatment
GCS motor 
score 3 or 
4, comatose 
and ventilator 
dependent 
after ROSC
33°C (32°C–
34°C)
36.8°C (36°C–
37.5°C)
120 h No difference in 
28-d mortality or 
12-mo survival with 
favorable neurological 
outcome or other 
secondary outcomes; 
culture-proven 
bacterial infection 
more common in 
TTM group; the 25 
survivors at 12 mo who 
received >30 min of 
CC had poor functional 
outcomes (PCPC ≥4)
CPR duration 
longer in TTM 
36°C–37.5°C 
group and 
fewer had 
bystander 
CPR; blinding 
of caregivers 
impossible
(Continued )
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Moler et al,142 
2015
International, 
multi-
institutional 
prospective RCT 
(September 1, 
2009–December 
31, 2012)
295 
Randomized; 
260 subjects 
with data, all 
OHCA who 
required ≥2 
min of CC, 
remained 
comatose 
and ventilator 
dependent;
155 assigned 
to TTM
48 h to <18 y of 
age; excluded 
if GCS motor 
score 5 or 6, 
major trauma, 
inability to 
randomize within 
6 h, decision 
to withhold 
aggressive 
treatment
GCS motor 
score 3 or 
4, comatose 
and ventilator 
dependent 
after ROSC
33°C (32°C–
34°C)
36.8°C (36°C–
37.5°C)
120 h No difference in 
28-d mortality 
(57% in TTM, 67% 
in control group, 
P=0.08), 12-mo 
survival (38% in TTM 
vs 29% in control) 
or in 12-mo survival 
with favorable 
neurological 
outcome or other 
secondary outcomes; 
no difference in 
complications 
(eg, bleeding, 
arrhythmias, 
infections), although 
hypokalemia and 
thrombocytopenia 
occurred more 
frequently in 
TTM group and 
renal replacement 
treatment used more 
often in control 
group; significant 
difference in survival 
time with TTM group, 
although this was a 
secondary outcome
Witnessed 
arrest, 39%, 
and 66% of 
these received 
bystander CPR;
72% of 
patients had 
respiratory 
cause of arrest; 
blinding of 
caregivers was 
impossible
Moler et al,141 
2017
International, 
multi-
institutional 
prospective RCT 
(September 1, 
2009–February 
27, 2015; 
stopped for 
futility)
329 Patients 
randomized; 
166 to 
control
(IHCA)
48 h to <18 y of 
age; excluded 
if GCS motor 
score 5 or 6, 
major trauma, 
inability to 
randomize within 
6 h, decision 
to withhold 
aggressive 
treatment
GCS motor 
score 3 or 
4; comatose 
and ventilator 
dependent 
after ROSC
33°C (32°C–
34°C)
36.8°C (36°C–
37.5°C)
120 h Survival at 28 d and 
survival with VABS-
II ≥70 at 1 y: 36% 
TTM vs 39% control 
(no difference); 
no difference in 
secondary outcomes, 
including alive at 1 y 
or change in VABS-II 
score from baseline; 
no difference in 
infection, blood 
product use, serious 
arrhythmias  
within 7 d
65% had either 
cardiac cause 
of arrest or 
CHD; blinding 
of caregivers 
was impossible
Scholefield et 
al,147 2015
Retrospective 
cohort enrolled 
January 
2004–December 
2010 after 
OHCA
73 Patients; 
38 
randomized 
to TTM
1 d to 16 y of 
age, admitted 
after OHCA with 
ROSC
Not stated 
although 
cited the 
ILCOR 
guidance 
for TTM 
for patients 
who remain 
comatose 
after ROSC 
from cardiac 
arrest
32°C–34°C; 4 
patients (11%) 
experienced 
“overshoot” 
cooling to 
<32°C and 
all died; only 
3% (1 patient) 
developed 
temperature 
>38°C
Called 
standard 
temperature 
management 
with rescue 
temperature-
controlling 
measures 
to keep 
temperature
≤38°C;
38% had fever 
>38°C
22.5 h Overall survival was 
29% and was not 
significantly different 
between TTM (34%) 
and control (23%) 
groups; study was 
underpowered to 
detect significant 
difference in hospital 
survival; TTM group 
had more bradycardia 
and hypotension and 
had longer LOS
Significantly 
more patients 
in TTM group 
(81% vs 47%) 
had bystander 
CPR; TTM used 
more often in 
patients with 
unknown 
cause of arrest 
and higher 
predicted 
mortality and 
used less in 
those with 
traumatic arrest 
(including TBI), 
so control 
group had 
more patients 
with traumatic 
arrest; study 
enrollment 
bridged a 
period of major 
change in basic 
life support 
guidelines
Table 13. Continued
Study, Year
Study Type; 
Years Enrolled n
Enrollment
Criteria
GCS/
Neurological
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Intervention
Temperature 
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Control
TTM
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Soar et al 2019 ILCOR CoSTR Summary
survival associated with the use of TTM 32°C to 34°C 
compared with TTM 36°C to 37.5°C.124,143,149
Adverse Outcomes: Infection
A pooled analysis of the 2 RCTs found no statistical dif-
ference in culture-proven infection from TTM 32°C to 
34°C compared with TTM 36°C to 37.5°C.141,142 Four 
cohort studies reported infection; unadjusted outcomes 
were not pooled, but none of the studies showed a 
statistically significant difference in infection with use 
of TTM 32°C to 34°C compared with TTM 36°C to 
37.5°C.124,144,146,149
Adverse Outcomes: Recurrent Cardiac Arrest
Pooled analysis of the 2 RCTs found no difference in the 
rate of recurrent cardiac arrest from TTM 32°C to 34°C 
compared with TTM 36°C to 37.5°C.141,142 Two cohort 
studies reported unadjusted recurrent cardiac arrest 
rates that could not be pooled; none of the individual 
studies showed statistically significant association of in-
creased recurrent arrest with the use of TTM 32°C to 
34°C compared with TTM 36°C to 37.5°C.124,149
Adverse Outcomes: Serious Bleeding
Pooled analysis of the 2 RCTs found a significant in-
crease in serious bleeding from TTM 32°C to 34°C com-
pared with TTM 36°C to 37.5°C.141,142 Two observation-
al cohort studies reported unadjusted odds ratios for 
serious bleeding; none of the individual studies showed 
association of statistically significant increase in bleed-
ing with the use of TTM 32°C to 34°C compared with 
TTM 36°C to 37.5°C.124,149
Adverse Outcomes: Arrhythmias
Pooled analysis of the 2 RCTs found no statistical in-
crease in arrhythmias from TTM 32°C to 34°C com-
pared with TTM 36°C to 37.5°C.141,142 Five observational 
studies reported unadjusted outcomes for arrhythmias; 
1 reported an association of a statistically significant 
increase in arrhythmias; the other 3 studies reported no 
statistically significant increase or decrease in arrhyth-
mias associated with the use of TTM 32°C to 34°C 
compared with TTM 36°C to 37.5°C.124,144,146,147,149
Subgroup Analysis: Location of Cardiac Arrest
For the predetermined subgroup analysis by location 
of arrest (OHCA or IHCA), no meta-analyses could be 
completed because there is only 1 RCT for each sub-
group and the observational studies had methodologi-
cal heterogeneity.
For OHCA, the single RCT did not find statistically 
significant benefit of TTM 32°C to 34°C compared with 
TTM 36°C to 37.5°C.142 One of the 3 cohort studies 
found (in unadjusted results) association of increased 
survival and good behavioral survival with 72 hours 
of TTM 32°C to 34°C compared with TTM 36°C to 
37.5°C.146 The other 2 cohort studies did not report 
statistically significant benefit or harm.143,147 An explor-
atory analysis was conducted to determine whether 
the addition of a hypothetical OHCA RCT that yielded 
results similar to the THAPCA OHCA study (Therapeu-
tic Hypothermia After Pediatric Cardiac Arrest) would 
change the pooled analysis CI to favor TTM 32°C to 
34°C.142 Enrollment of 200 patients in such a hypotheti-
cal RCT would be required to demonstrate a statistically 
significant benefit for favorable neurological outcome 
at 1 year.
The IHCA RCT did not find statistical benefit or harm 
of TTM 32°C to 34°C compared with TTM 36°C to 
37.5°C.141 The point estimates for outcomes of 3 dif-
ferent observational cohort studies are on both sides of 
the null effect.144,148,149 An exploratory analysis indicated 
that an additional hypothetical RCT of 6000 patients 
with an outcome similar to the THAPCA IHCA RCT141 
would be required to demonstrate a statistically signifi-
cant harm of TTM 32°C to 34°C in favorable neuro-
Torres-Andres 
et al,148 2018
Retrospective 
observational 
study of all 
witnessed 
OHCAs and 
IHCAs between 
May 2007 
and July 2015 
treated with 
ECPR
58 
Consecutive 
patients 
receiving 
ECPR; 28 also 
treated with 
TTM
Witnessed 
IHCA (only 3/58 
patients) or 
OHCA; receipt 
of advanced 
CPR, no ROSC 
within 15 min 
of CPR; no 
contraindication 
to mechanical 
circulatory 
support; 
hypothermia was 
at discretion of 
care team
Not stated 34°C–35°C Controlled 
normothermia 
avoiding body 
temperature 
>37°C
 Overall survival to 
hospital discharge, 
65.5%; 3-y survival, 
62.1%; survival to 
hospital discharge 
significantly higher 
among those treated 
with TTM (75%) 
vs control subjects 
(55%) with good QOL 
inventory and family 
functioning; 50% of 
survivors had evidence 
of intracranial 
injuries (vs 58.3% of 
nonsurvivors)
Nonsurvivors 
more likely to 
have >1 ECPR 
event
AHA indicates American Heart Association; CC, chest compressions; CHD, congenital heart disease; CPC, Cerebral Performance Category; CPR, cardiopulmonary resuscitation; ECPR, 
extracorporeal cardiopulmonary resuscitation; ED, emergency department; GCS, Glasgow Coma Scale; ICU, intensive care unit; IHCA, in-hospital cardiac arrest; ILCOR, International Liaison 
Committee on Resuscitation; LOS, length of stay; OHCA, out-of-hospital cardiac arrest; PCPC, Pediatric Cerebral Performance Category; QOL, quality of life; RCT, randomized controlled trial; 
ROSC, return of spontaneous circulation; TBI, traumatic brain injury; TTM, targeted temperature management; and VABS-II, Vineland Adaptive Behavior Scales II.138
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logical outcome at 1 year compared with TTM 36°C to 
37.5°C.
Subgroup Analysis: Cause of Arrest
Two retrospective observational cohort studies of car-
diac arrest with presumed cardiac cause could not be 
pooled but separately reported no significant benefit or 
harm in short-term survival associated with TTM 32°C 
to 36°C compared with TTM 36°C to 37.5°C (or no 
TTM).144,148
Two observational cohort studies (and a pilot pub-
lication of one of those studies) reported favorable 
neurological outcome and survival outcomes for pa-
tients with predominantly (>80%) presumed asphyxial 
origin.124,145,146 A high risk of bias and lack of adjusted 
outcomes precluded the pooling of data. One OHCA 
study found a statistically significant benefit for both 
favorable neurological outcome and survival associated 
with TTM 32°C to 36°C for 72 hours.146 All of the point 
estimates for outcomes favored TTM 32°C to 36°C.
The THAPCA OHCA study published a nonrandom-
ized subgroup analysis of drowning as a cause.150 There 
was no statistically significant benefit of the interven-
tion for survival or favorable neurological outcome.
Subgroup Analysis: ECMO
Although some patients in several of the studies un-
derwent ECMO, outcome data were available from 
only 2 studies. The THAPCA IHCA RCT (nonrandom-
ized cointervention, of low-certainty evidence) found 
no statistically significant difference in long-term favor-
able neurological outcome (at 1 year) for TTM 32°C 
to 34°C compared with TTM 36°C to 37.5°C.141 In 1 
observational cohort study, all patients received ECMO; 
that study reported no statistical increase in short-term 
survival.148
Treatment Recommendations
We suggest that for infants and children with OHCA, 
TTM be used in the post–cardiac arrest period to main-
tain a central temperature <37.5°C (weak recommen-
dation, moderate certainty of evidence). On the basis 
of 2 randomized trials and 8 retrospective observational 
cohort studies that provided comparative data on favor-
able neurological outcome, survival, and in-hospital ad-
verse events, there is inconclusive evidence to support 
or refute the use of TTM 32°C to 34°C compared with 
TTM 36°C to 37.5°C (or an alternative temperature) for 
children who achieve ROSC after cardiac arrest.
Justification and Evidence to Decision Framework 
Highlights
The evidence in this review is dominated by the 2 THAP-
CA RCTs.141,142 These studies included only children 2 
days to 18 years of age who had received at least 2 
minutes of CPR and who remained comatose and ven-
tilator dependent after ROSC. There were many patient 
exclusions, including the use of ECMO, severe trauma, 
previous cardiac arrest, preexisting life-limiting condi-
tions, severe bleeding, and continuous epinephrine in-
fusion. The findings of this review should be considered 
in the context of this limitation.
In making this recommendation, the task force pre-
ferred the use of TTM 32°C to 34°C as opposed to TTM 
36°C to 37.5°C because, although the THAPCA OHCA 
study142 did not demonstrate success for the primary 
outcome (favorable neurological status at 1 year), it 
was underpowered to show a significant difference for 
survival, for which the lower 95% CI approached 1. 
The point estimates for survival in the 3 cohort studies 
of OHCA or presumed asphyxial arrest124,145,146 favored 
TTM 32°C to 34°C. There were insufficient data on pa-
tients with IHCA, who represent a population with dif-
ferent preexisting conditions and cause of arrest.
The task force noted that hyperthermia occurs fre-
quently in the postarrest period; fever is potentially 
harmful and should be avoided. Finally, the provision 
of TTM can be resource intensive. These resources, the 
associated expertise necessary to deliver and maintain 
TTM, and the presence of appropriate systems of criti-
cal care are required to provide optimal post-ROSC care. 
The task force noted that the application of TTM may 
require sedation, analgesia, and neuromuscular block-
ing drugs that will modify neurological assessment.
Knowledge Gaps
This evidence evaluation did not address training, lo-
gistical, operational, or economic issues pertaining to 
TTM. It also did not compare other temperature ranges 
and did not address the duration of TTM. In addition, 
the task force identified knowledge gaps requiring fur-
ther investigation:
• The use of TTM 32°C to 34°C for children after 
OHCA
• Asphyxial arrest and the use of TTM 36°C to 
37.5°C in patients with IHCA
NLS TASK FORCE
Initial Oxygen Concentration for Term 
Infants at Birth
Administration of high oxygen concentrations leads 
to free radical formation and may be toxic to lungs, 
eyes, brains, and other organs of the newborn.151,152 In 
2010, the ILCOR NLS Task Force CoSTR update noted 
that it was best to start with 21% oxygen when term 
newborns received positive-pressure ventilation in the 
delivery room. The recommendation was based on a 
meta-analysis that found lower mortality when room 
air instead of 100% oxygen was used.153 The evidence 
review for this question did not use GRADE methodol-
ogy2 to analyze the published studies. This topic was 
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not addressed for term infants in the 2015 CoSTR up-
date.154 Questions remain about the risks of hypoxemia 
versus hyperoxemia for late preterm and term new-
borns who receive respiratory support in the delivery 
room. As a consequence, the ILCOR NLS Task Force 
undertook an SR with meta-analysis of the relevant 
available evidence using GRADE methodology2 on the 
topic of lower versus higher concentrations of oxygen 
for the initiation of resuscitation of newborn infants at 
≥35 weeks’ gestation.9
Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Newborn infants (≥35 weeks’ gestation) 
who receive respiratory support at birth
Intervention: Lower initial oxygen concentration 
(≤50% O2)
Comparison: Higher initial oxygen concentration 
(>50% O2)
Outcomes:
• Primary: All-cause short-term mortality (in hospital 
or 30 days)
• Secondary: All-cause long-term mortality (13 
years); long-term neurodevelopmental impairment 
(NDI; 13 years); hypoxic-ischemic encephalopathy 
(Sarnat stage 2–3)155
Study designs: RCTs, qRCTs, and nonrandomized co-
hort studies included; animal studies, unpublished stud-
ies, and published abstracts (eg, conference abstracts) 
excluded
Time frame: 1980 to August 10, 2018
A priori subgroups to be examined: Gestational age 
(≥35, ≥37 weeks); grouped lower and higher oxygen 
concentrations; explicit oxygen saturation targeting 
versus no oxygen saturation targeting
PROSPERO registration: CRD42018084902
Consensus on Science
The SR identified 10 trials and 2 follow-up studies in-
volving 2164 newborns, but 3 of the trials had criti-
cal risk of bias and were included in only the sensitiv-
ity analyses.9 Data from 1469 term and late preterm 
infants (≥35 weeks’ gestation) in 7 randomized and 
qRCTs were included. All identified studies compared 
21% (or air) with 100% oxygen concentration; no oth-
er initial oxygen concentrations were reported. No data 
specific to ≥37 weeks’ gestation were found, and none 
of the studies used targeted oxygen saturation (Spo2) 
monitoring.
A draft CoSTR document based on the SR was 
posted for a 2-week public commenting period on 
January 15, 2019.156 During the comment period, the 
draft CoSTR was viewed 3564 times. The NLS Task 
Force received 47 comments that were subsequently 
sorted into 4 main categories: (1) agreement with the 
CoSTR as written; (2) responses that demonstrated a 
need for more explicit emphasis that the intent of the 
population, intervention, comparator, outcome, study 
design, and time frame was to address initial oxygen 
concentration (not a static delivery concentration); (3) 
questions about special situations such as oxygen use 
during cardiac compressions or in the unique circum-
stance of newborns with anomalies such as pulmonary 
hypoplasia or congenital diaphragmatic hernia; and (4) 
a desire for stronger emphasis on the need for more 
evidence using current methods of oxygen monitoring 
and titration and additional interval oxygen concentra-
tions for infants at ≥35 weeks’ gestation. In response to 
the public comments, the NLS Task Force included addi-
tional information to address questions and comments 
about the 3 main categories of concerns.
Short-Term Mortality (In Hospital or 30 Days)
For this critical outcome, evidence of low certainty 
(downgraded for risk of bias and imprecision) from 7 
RCTs (and qRCTs) involving 1469 newborn infants at 
≥35 weeks’ gestation receiving respiratory support 
at birth showed benefit of starting with 21% oxygen 
compared with 100% oxygen (RR, 0.73 [95% CI, 0.57–
0.94]; I2=0%); 46 of 1000 fewer (95% CI, 73–10 few-
er) babies died when respiratory support at birth was 
started with 21% compared with 100% oxygen.157–163
Long-Term Mortality (1–3 Years)
For this critical outcome, no evidence was identified.
NDI (13 Years)
Among survivors who were assessed for this critical 
outcome, evidence of very low certainty (downgrad-
ed for risk of bias and imprecision) from 2 RCTs (and 
qRCTs) involving 360 term and late preterm newborns 
(≥35 weeks) who received respiratory support at birth 
showed no statistically significant benefit or harm of 
starting with 21% compared with 100% oxygen (RR, 
1.41 [95% CI, 0.77–2.60]; I2=0%): 36 of 1000 more 
(95% CI, 20 fewer–142 more) babies with NDI when 
respiratory support at birth was started with 21% com-
pared with 100% oxygen.161,164
Hypoxic-Ischemic Encephalopathy (Sarnat Stage 2–3)155
For this critical outcome, evidence of low certainty 
(downgraded for risk of bias and imprecision) from 5 
RCTs (and qRCTs) involving 1359 term and late pre-
term newborns (≥35 weeks’ gestation) receiving respi-
ratory support at delivery showed no statistically sig-
nificant benefit or harm of 21% compared with 100% 
oxygen (RR, 0.90 [95% CI, 0.71–1.14]; I2=8%): 20 per 
1000 fewer (95% CI, 57 fewer–27 more) babies with 
hypoxic-ischemic encephalopathy when respiratory 
support at birth was started with 21% compared with 
100% oxygen.157,158,160,161,163
Subgroup Infants ≥37 Weeks’ Gestation 
No data for the planned subgroup analysis for infants 
of ≥37 weeks’ gestation were found.
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Intermediate Initial Oxygen Concentrations
No studies were identified that compared any interme-
diate initial oxygen concentrations.
Oxygen Saturation Targeting Versus No Oxygen 
Saturation Targeting
No studies were identified that used Spo2 targeting.
Treatment Recommendations
For newborn infants at ≥35 weeks’ gestation receiving 
respiratory support at birth, we suggest starting with 
21% oxygen (air; weak recommendation, low certain-
ty of evidence). We recommend against starting with 
100% oxygen (strong recommendation, low certainty 
of evidence).
Justification and Evidence to Decision Framework 
Highlights
Parents and clinicians rate mortality as a critical out-
come. Despite the low certainty of the evidence, the 
large reduction in the primary outcome of short-term 
mortality (number needed to treat, 22) with no demon-
strated adverse effects favors the use of 21% oxygen 
as the initial gas for resuscitation for newborns at ≥35 
weeks’ gestation. Although there are no published cost 
data, it is likely that initiating resuscitation with 21% 
oxygen does not add cost and might result in cost sav-
ings compared with the use of initial 100% oxygen in 
some settings. Babies born in low-resource settings 
demonstrate increased mortality and morbidity. There-
fore, it is plausible that using 21% oxygen compared 
with 100% oxygen has greater impact in low-resource 
settings. Use of 21% oxygen for initial resuscitation is 
universally feasible.
To be clear, we emphasize that the recommendation 
for 21% oxygen refers to the initial concentration of 
oxygen at the initiation of respiratory support. It does 
not address the question of how to titrate the oxygen 
concentration as resuscitation progresses; no evidence 
was found to guide this aspect of oxygen delivery. Once 
such evidence is published, the NLS Task Force will initi-
ate an SR to assess the effect and optimal methods of 
titration of oxygen concentrations during resuscitation. 
We found no studies that evaluated the initial oxygen 
concentration for specific special circumstances such as 
congenital diaphragmatic hernia or pulmonary hypo-
plasia.
Knowledge Gaps
The NLS Task Force identified the following knowledge 
gaps requiring further investigation:
• Studies in late preterm (35–36 weeks’ gestation) 
infants: few of these infants were included in the 
published studies, leading to lower certainty in the 
evidence for this gestational age group
• Research to assess the impact of titration of oxy-
gen to oxyhemoglobin saturation (Spo2) targets as 
the resuscitation progresses: monitoring Spo2 and 
titration of oxygen concentration were not routinely 
used in the studies included in the SR for this CoSTR
• Comparison of initial oxygen concentrations inter-
mediate between 21% and 100%: in the SR for 
this CoSTR, no studies were found that compared 
any oxygen concentrations other than 21% versus 
100%
• Determination of whether delayed cord clamp-
ing affects the impact of initial inspired oxygen 
concentration
• The effect of initial oxygen concentrations on long-
term NDI; studies published to date have been of 
very low certainty of evidence
• The optimal initial oxygen concentrations needed 
in special circumstances such as newborns with 
pulmonary hypoplasia, congenital diaphragmatic 
hernia, and other anomalies
Initial Oxygen Concentration for Preterm 
Infants at Birth
Preterm newborn infants are particularly vulnerable to 
oxidative stress resulting from reduced antioxidant de-
fenses and frequent exposure to oxygen during stabili-
zation in the delivery room.165 Many common complica-
tions of prematurity are associated with oxygen toxicity, 
including bronchopulmonary dysplasia, retinopathy of 
prematurity, and intraventricular hemorrhage. Medical 
practitioners who stabilize preterm infants at birth must 
try to prevent hypoxia while limiting excess oxygen to 
prevent toxic effects. In 2015, the ILCOR NLS Task Force 
CoSTR update recommended starting with 21% to 
30% oxygen for preterm newborns needing respira-
tory support in the delivery room.154 This was based on 
meta-analysis findings of no benefit for any important 
or critical outcomes when high oxygen concentrations 
were used. Additional studies are now available, so 
the ILCOR NLS Task Force undertook an SR with meta-
analysis using GRADE methodology2 of the relevant 
available evidence on the effects of lower versus higher 
oxygen concentrations for initiation of resuscitation of 
preterm newborn infants.10
Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Preterm newborn infants (<35 weeks’ esti-
mated gestational age) who receive respiratory support 
at birth
Intervention: Lower initial oxygen concentration 
(≤50% O2)
Comparison: Higher initial oxygen concentration 
(>50% O2)
Outcomes:
• Primary: All-cause short-term mortality (in hospital 
or 30 days)
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• Secondary: All-cause long-term mortality (1–3 
years); long-term NDI (1–3 years); retinopathy of 
prematurity (stages III–V);166 necrotizing enteroco-
litis stage II (pneumatosis) or III (surgical)167; bron-
chopulmonary dysplasia (moderate to severe)168; 
major intraventricular hemorrhage (grade III–IV)169; 
and time to heart rate >100 bpm
Study designs: RCTs, qRCTs, and nonrandomized co-
hort studies included; animal studies, case series, un-
published studies, and published abstracts (eg, confer-
ence abstracts) excluded
Time frame: 1980 to August 10, 2018
A priori subgroups to be examined: Gestational age 
(≤32, ≤28 weeks); grouped lower and higher initial 
oxygen concentrations (21% O2 compared with 100% 
O2, 21%–30% compared with 80%–100% only, 30% 
compared with 90%–100%, 50% compared with 
100%, 30% compared with 60%–65%); and explicit 
Spo2 targeting versus no Spo2 targeting
PROSPERO registration: CRD42018084902
Consensus on Science
The SR found 16 eligible studies that included 5697 
preterm newborns.10 This constituted 10 RCTs, 2 fol-
low-up studies, and 4 observational cohort studies. The 
majority (9 of 10) of the RCTs used 21% to 30% as the 
initial low oxygen concentration,170–178 with only 1 small 
RCT using 50% for the initial low oxygen group.179 All 
observational studies used 21% oxygen as the initial 
low oxygen concentration.180–183 Six of 10 RCTs used 
100% oxygen,171,173–175,178,179 1 RCT used 90%,172 1 RCT 
used 80%,170 and 2 RCTs used >60%176,177 as the high 
initial oxygen concentration. All observational studies 
used 100% as the high initial oxygen concentration. 
A majority of RCTs (8 of 10)171–178 and all of the ob-
servational cohort studies180–183 used Spo2 targeting as 
a cointervention. All results are presented as RR with 
95% CI and absolute difference with 95% CI.
A draft CoSTR document based on the SR was posted 
for a 2-week public commenting period on January 15, 
2019.184 During the comment period, the draft CoSTR 
was viewed 7387 times, suggesting intense interest 
within the global neonatal community. The NLS Task 
Force received 52 comments that were subsequently 
grouped into 3 categories: those that agreed with the 
draft CoSTR as written, those that wanted clarification 
on what “no benefit or harm” truly meant, and those 
that expressed disappointment that the science does 
not yet provide a clearer answer. As a result of the pub-
lic comments, the NLS Task Force included additional 
information to address these concerns.
All Preterm Gestational Ages Combined (<35 Weeks’ 
Gestation)
Overall, evidence of very low certainty (downgraded for 
risk of bias and imprecision) for newborn infants at <35 
weeks’ gestation receiving respiratory support at birth 
showed no statistically significant benefit or harm of 
lower initial oxygen concentration (≤50%) compared 
with higher initial oxygen concentration (>50%) for the 
following critical outcomes (see Table 14 for data): all-
cause short-term mortality (in hospital or 30 days), all-
cause long-term mortality (1–3 years), long-term NDI 
(moderate to severe, 1–3 years), retinopathy of pre-
maturity (grade III–V),166 necrotizing enterocolitis (Bell 
grade II–III),167 bronchopulmonary dysplasia (moder-
ate to severe),168 or major intraventricular hemorrhage 
(grade III–IV).169 For the important outcome of time to 
heart rate >100 bpm after delivery, the limitation of the 
direct evidence for newborn infants at <35 weeks’ ges-
tation precluded meta-analysis.
Subgroup Newborn Infants at ≤32 Weeks’ Gestation 
For the critical outcome of all-cause short-term mor-
tality (in hospital or 30 days), the evidence of very low 
certainty (downgraded for risk of bias and impreci-
sion) from 8 RCTs with 837 newborn infants at ≤32 
weeks’ gestation receiving respiratory support at birth 
showed no statistically significant benefit or harm of 
lower initial oxygen concentration compared with 
higher initial oxygen concentration (RR, 0.93 [95% CI, 
0.55–1.55]; I2=15%): 6 of 1000 fewer (95% CI, 39 
fewer–47 more) with short-term mortality when lower 
compared with higher initial oxygen concentration 
was used.171–173,175–179
Subgroup Newborn Infants at ≤28 Weeks’ Gestation 
For the subgroup analysis of newborn infants at ≤28 
weeks’ gestation receiving respiratory support at birth, 
evidence of very low certainty (downgraded for risk of 
bias and imprecision) showed no statistically significant 
benefit or harm of lower initial oxygen concentration 
(≤50%) compared with higher initial oxygen concen-
tration (>50%) for the following critical outcomes (see 
Table 15 for data): short-term mortality (in hospital or 
30 days), long-term mortality (1–3 years), long-term 
NDI (moderate to severe, 1–3 years), retinopathy of pre-
maturity (grade III–V),166 necrotizing enterocolitis (Bell 
grade II–III),167 bronchopulmonary dysplasia (moder-
ate to severe),168 or major intraventricular hemorrhage 
(grade III–IV).169
Subgroup of 21% Compared With 100% Oxygen 
Concentration (<35 Weeks’ Gestation)
For the critical outcome of all-cause short-term mortali-
ty (in hospital or 30 days), evidence of very low certainty 
(downgraded for risk of bias and imprecision) from 4 
RCTs with 484 newborn infants at <35 weeks’ gesta-
tion receiving respiratory support at birth showed no 
statistically significant benefit or harm of initial room air 
(21% O2) compared with initial 100% oxygen concen-
tration (RR, 1.58 [95% CI, 0.70–3.55]; I2=4%): 26 per 
1000 more (95% CI, 14 fewer–115 more) with short-
term mortality when lower initial oxygen concentration 
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(21%) compared with higher initial oxygen concentra-
tion (100%) was used.171,173,175,178
• For the critical outcome of all-cause long-term 
mortality (1–3 years), in newborns at <35 weeks’ 
gestation, the results are the same as for all groups 
at <35 weeks’ gestation.
• For the critical outcome of long-term NDI (mod-
erate to severe, 1–3 years) in preterm newborns 
(<35 weeks’ gestation), the results are the same as 
for all groups at <35 weeks’ gestation.
Additional subgroup analyses that evaluated the effect 
of varying the definition of low and high oxygen con-
centration (21%–30% compared with 80%–100% 
only; 30% compared with 90%–100%; 50% com-
pared with 100%; 30% compared with 60%–65%) 
and whether Spo2 targeting as a cointervention had 
any impact found no differences in primary and sec-
ondary outcomes.10 When data from 2 observational 
cohort studies with 1225 newborns182,183 were pooled, 
initiating resuscitation with lower oxygen was associ-
ated with a statistically significant benefit in long-term 
mortality for all preterm newborns and the subgroup 
of ≤28 weeks’ gestation (RR, 0.77 [95% CI, 0.59–
0.99]; I2=6%).10
Table 14. Meta-Analysis of RCTs Comparing Initial Low and High Oxygen Concentration for All Preterm Gestational Ages Combined (<35 Weeks’ 
Gestation)
Outcome
Article With Outcome 
of Interest Total, n
Certainty of
Evidence RR (95% CI); I 2 Absolute Difference (95% CI)
Short-term mortality (in 
hospital or 30 d)
Lundstrøm et al,170 1995 
Harling et al,179 2005
Wang et al,171 2008 
Vento et al,172 2009 
Rabi et al,173 2011 
Armanian and Badiee,174 
2012 
Kapadia et al,175 2013 
Aguar et al,176 2013 
Rook et al,177 2014 
Oei et al,178 2017
968 Very low 0.83 (0.50–1.37); 18% 15/1000 fewer deaths when lower vs higher 
initial oxygen concentration was used (44 
fewer–32 more)
Long-term mortality 
(1–3 y)
Boronat et al,185 2016 
Thamrin et al,186 2018
491 Very low 1.05 (0.32–3.39); 79% 5/1000 more deaths when lower vs higher initial 
oxygen concentration was used (71 fewer–248 
more)
NDI (moderate to 
severe at 1–3 y)
Boronat et al,185 2016 
Thamrin et al,186 2018
389 Very low 1.14 (0.78–1.67); 0% 27/1000 more with NDI when lower vs higher 
initial oxygen concentration was used (42 
fewer–129 more)
Retinopathy of 
prematurity (grade 
III–V)
Lundstrøm et al,170 1995 
Harling et al,179 2005
Vento et al,172 2009 
Kapadia et al,175 2013 
Aguar et al,176 2013 
Rook et al,177 2014 
Oei et al,178 2017
806 Very low 0.73 (0.42–1.27); 0% 19/1000 fewer with retinopathy of prematurity 
(grade III–V) when lower vs higher initial oxygen 
concentration was used (42 fewer–19 more)
Necrotizing 
enterocolitis (Bell grade 
II–III)
Lundstrøm et al,170 1995 
Harling et al,179 2005
Wang et al,171 2008 
Vento et al,172 2009 
Kapadia et al,175 2013 
Aguar et al,176 2013 
Rook et al,177 2014 
Oei et al,178 2017
847 Very low 1.34 (0.63–2.84); 0% 12/1000 more with necrotizing enterocolitis when 
lower initial vs higher initial oxygen concentration 
was used (13 fewer–65 more)
Bronchopulmonary 
dysplasia (moderate to 
severe)
Harling et al,179 2005
Wang et al,171 2008 
Vento et al,172 2009 
Rabi et al,173 2011 
Kapadia et al,175 2013 
Aguar et al,176 2013 
Rook et al,177 2014 
Oei et al,178 2017
843 Very low 1.00 (0.71–1.400); 
47%
0/1000 fewer with bronchopulmonary dysplasia 
when lower vs higher initial oxygen concentration 
was used (77 fewer–107 more)
Major intraventricular 
hemorrhage (grade 
III–IV)
Lundstrøm et al,170 1995 
Wang et al,171 2008 
Vento et al,172 2009 
Kapadia et al,175 2013 
Aguar et al,176 2013 
Rook et al,177 2014 
Oei et al,178 2017
795 Very low 0.96 (0.61–1.51); 0% 3/1000 fewer with major intraventricular 
hemorrhage (grade III–IV) when lower vs higher 
initial oxygen concentration was used (32 
fewer–42 more)
NDI indicates neurodevelopmental impairment; RCT, randomized controlled trial; and RR, relative risk.
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Treatment Recommendations
For preterm newborn infants (<35 weeks’ gestation) who 
receive respiratory support at birth, we suggest starting 
with a lower oxygen concentration (21%–30%) rather 
than higher initial oxygen concentration (60%–100%; 
weak recommendation, very low certainty of evidence). 
We suggest the range of 21% to 30% oxygen because 
all trials but one used this for the low oxygen concentra-
tion group. Subsequent titration of oxygen concentra-
tion using pulse oximetry is advised (weak recommenda-
tion, very low certainty of evidence).
Until further evidence is available, implementation of 
the suggested initial oxygen concentration between 21% 
and 30% should be based on local practice considerations 
and should be reevaluated with ongoing audit of care.
Justification and Evidence to Decision  
Framework Highlights
Balancing the benefits and serious potential harm of 
low versus high oxygen concentrations in neonatal care 
is a continuing concern, particularly for preterm infants. 
Decades of research clearly demonstrate that oxygen 
exposure is a determinant of critical neonatal outcomes 
in preterm infants. Concern remains that if the preterm 
infant requires resuscitation immediately after birth, the 
initial oxygen concentration to which the infant is ex-
posed may be a critical contributor to outcomes, regard-
less of subsequent oxygen exposure. Both parents and 
clinicians rate the outcomes assessed in this SR as either 
critical or important. For all of the critical outcomes as-
sessed in the meta-analyses of RCTs, the 95% CIs of RRs 
were wide enough to include both potential harm and 
potential benefit. Thus, it is unclear whether initial low 
or high oxygen concentrations may have undesirable ef-
fects. In suggesting starting with low oxygen concentra-
tions (21%–30%), we place value on avoiding exposure 
of preterm babies to additional oxygen without proven 
benefit for critical or important outcomes because we 
are cognizant of harms in newborn animals and in-
Table 15. Meta-Analysis of RCTs Comparing Initial Low and High Oxygen Concentration for ≤28-Week Gestational Age Subgroup
Outcome
Article With Outcome 
of Interest Total, n
Certainty of
Evidence
RR
(95% CI); I 2 Absolute Difference (95% CI)
Short-term 
mortality (in 
hospital or 30 d)
Wang et al,171 2008 
Vento et al,172 2009 
Rabi et al,173 2011 
Kapadia et al,175 2013 
Aguar et al,176 2013 
Rook et al,177 2014 
Oei et al,178 2017
467 Very low 0.92 (0.43–1.94); 45% 10/1000 fewer with short-term mortality when 
lower vs higher initial oxygen concentration was 
used (70 fewer–116 more per 1000)
Long-term mortality 
(1–3 y)
Thamrin et al,186 2018 86 Very low 2.11 (0.86–5.19); NA 145/1000 more with long-term mortality when 
lower vs higher initial oxygen concentration was 
used (18 fewer–547 more per 1000)
NDI (moderate to 
severe at 1–3 y)
Thamrin et al,186 2018 69 Very low 1.08 (0.58–2.03); NA 28/1000 more with long-term NDI when lower 
vs higher initial oxygen concentration was used 
(147 fewer–360 more per 1000)
Retinopathy of 
prematurity (grade 
III–V)
Wang et al,171 2008 
Vento et al,172 2009 
Kapadia et al,175 2013 
Aguar et al,176 2013 
Rook et al,177 2014 
Oei et al,178 2017
441 Very low 0.75 (0.43–1.33); 0% 30/1000 fewer with retinopathy of prematurity 
when lower vs higher initial oxygen concentration 
was used (67 fewer–39 more per 1000)
Necrotizing 
enterocolitis (Bell 
grade II–III)
Wang et al,171 2008 
Vento et al,172 2009 
Kapadia et al,175 2013 
Aguar et al,176 2013 
Rook et al,177 2014 
Oei et al,178 2017
441 Very low 1.62 (0.66–3.99); 0% 20/1000 more with necrotizing enterocolitis 
when lower vs higher initial oxygen concentration 
was used (11 fewer–95 more per 1000)
Bronchopulmonary 
dysplasia (moderate 
to severe)
Wang et al,171 2008 
Vento et al,172 2009 
Rabi et al,173 2011 
Kapadia et al,175 2013 
Aguar et al,176 2013 
Rook et al,177 2014 
Oei et al,178 2017
467 Very low 0.90 (0.64–1.28); 31% 37/1000 fewer with bronchopulmonary dysplasia 
when lower vs higher initial oxygen concentration 
was used (132 fewer–102 more per 1000)
Major 
intraventricular 
hemorrhage (grade 
III–IV)
Wang et al,171 2008 
Vento et al,172 2009 
Kapadia et al,175 2013 
Aguar et al,176 2013 
Rook et al,177 2014 
Oei et al,178 2017
441 Very low 0.84 (0.50–1.40); 12% 23/1000 fewer with major intraventricular 
hemorrhage (grade III–IV) when lower vs higher 
initial oxygen concentration was used (73 
fewer–58 more per 1000)
NDI indicates neurodevelopmental impairment; RCT, randomized controlled trial; and RR, relative risk.
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creased neonatal mortality in term infants exposed to 
high initial oxygen concentration.151,187 This review ad-
dressed only the initial concentration of oxygen and 
therefore does not include any recommendation for 
subsequent administration or titration of oxygen. Sub-
sequent titration of supplementary oxygen should be 
based on published Spo2 target ranges.
The a priori comparisons evaluated only an initial 
oxygen concentration of 21% to 30% versus 80% 
to 100%, which therefore influences the recommen-
dation. We recognize that no studies have compared 
the safety or efficacy of beginning resuscitation with 
21% oxygen and intermediate concentrations such as 
30% oxygen. We emphasize that the included stud-
ies measured only the effect of varying initial inspired 
oxygen concentrations and were not designed to as-
sess the safety or efficacy of different Spo2 targets. As 
outlined above, careful attention should be paid to the 
initial and cumulative oxygen loads under the investi-
gated regimens. Therefore, starting at a lower oxygen 
concentration (21%–30%) with the option to titrate 
according to Spo2 aiming for published Spo2 target 
ranges provides an option of minimizing oxygen expo-
sure at birth.
Knowledge Gaps
The NLS Task Force identified the following knowledge 
gaps requiring further investigation:
• High-quality studies with appropriate power to 
determine optimal initial oxygen because the 95% 
CI for the primary outcome in most studies identi-
fied in this review includes both harm and benefit
• Further evidence from randomized studies on 
long-term NDI outcomes
• Studies to address the actual oxygen requirements 
for specific gestational age groups
• Further evidence to identify the optimal Spo2 tar-
gets for preterm infants
• Evidence to identify the optimal methods of titrat-
ing oxygen for preterm infants in the delivery room
• Potential effects of delayed cord clamping on the 
impact of initial inspired oxygen concentration for 
preterm infants
EIT AND ALS TASK FORCES
CACs Versus Non-CACs
CACs are hospitals providing evidence-based resusci-
tation treatments, including emergency interventional 
cardiology, bundled critical care with TTM, and pro-
tocolized cardiorespiratory support and prognostica-
tion.48,63
This population, intervention, comparator, out-
come, study design, and time frame was prioritized 
for review by the EIT and ALS Task Forces on the basis 
of the publication of several large registry studies188,189 
since the 2015 ILCOR ALS48,63 and EIT CoSTRs.190,191 In 
the following sections, we present a summary of the 
evidence identified by the ILCOR SR11 and the web-
posted CoSTR about the effects of CACs.192 One ques-
tion was posted during the comment period on the 
definition of CACs, and we have provided that in this 
introduction.
Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Adults with attempted resuscitation after 
nontraumatic IHCA or OHCA
Intervention: Specialized CAC care
Comparators: Care at non-CAC
Outcomes:
• Primary outcome: survival at 30 days or hospital 
discharge with favorable neurological outcome 
(CPC 1 or 2 or modified Rankin Scale score 0–3)
• Secondary outcomes: ROSC after hospital admis-
sion for patients with ongoing CPR and survival at 
30 days or hospital discharge
Study designs: Published RCTs and nonrandomized 
studies (non-RCTs, interrupted time series, controlled 
before-and-after studies, cohort studies) reporting data 
from adult patients
Time frame: All years and all languages included 
(provided there was an English abstract); literature 
search updated on August 1, 2018
PROSPERO registration: CRD42018091427
Consensus on Science
A total of 21 observational studies188,189,193–211 and 
1 pilot randomized trial212 were included in the SR.11 
Of these, 17 observational studies were ultimately in-
cluded in the meta-analysis.188,189,193–199,204–211 All studies 
were in OHCA cohorts; 1 study200 also included patients 
with IHCA, but outcomes were not reported separately.
The observational studies provided very low certainty 
of evidence for all outcomes. The included studies all 
reported outcomes from patients with OHCA who were 
cared for at a CAC compared with those cared for at a 
non-CAC. The manner of arrival at a CAC or non-CAC 
varied greatly across studies (ie, prehospital triage of all 
patients to the closest hospital, prehospital triage of se-
lect patients to a CAC, prehospital triage of all patients 
to a CAC, secondary interhospital transfer from a non-
CAC to a CAC, or not described). Given the potential 
for referral bias and other confounding variables, only 
data from studies reporting adjusted measures of as-
sociation were pooled in the meta-analysis.
CACs were associated with favorable neurological 
outcome and survival when examined at hospital dis-
charge, but this was nonsignificant when examined at 
30 days (Table 16).
In addition to the pooled data, 3 observational stud-
ies looking exclusively at long-term outcomes of patients 
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discharged alive from hospitals reported that care at a 
CAC was associated with better patient survival.199,200,202
Preplanned subgroup analyses identified additional 
information about the effects of primary transport versus 
secondary transfer of patients to CACs and about the 
outcomes of patients with shockable versus nonshock-
able rhythms. Four observational studies examined the 
potential impact of transfer on patient outcomes after 
OHCA.189,199,209,211 One study211 reported higher adjusted 
patient survival associated with direct transfer to a CAC 
compared with patient survival among those who un-
derwent secondary interfacility transfer (odds ratio, 1.97 
[95% CI, 1.13–3.43]). Two other studies189,199 reported 
no difference in survival between direct transport and 
secondary transfer of patients to a CAC. One study209 
reported higher adjusted survival in patients who un-
derwent a secondary transfer to a CAC compared with 
those who remained at the initial treating non-CACs 
(odds ratio, 1.59 [95% CI, 1.30–1.93]). One additional 
observational study194 reported higher adjusted patient 
survival to hospital discharge associated with bypassing 
the nearest non-CAC and transporting patients directly 
to a CAC compared with transporting patients to non-
CACs (odds ratio, 3.02 [95% CI, 2.01–4.53]).
Eight observational studies reported outcomes strati-
fied by arresting rhythm into shockable or nonshock-
able cohorts, but the findings were inconsistent, most 
reported unadjusted data, and the studies were too 
heterogeneous to pool.189,193,195,199,203,205,206,208
Treatment Recommendations From the EIT and 
ALS Task Forces
We suggest that adult patients with nontraumatic 
OHCA be cared for in CACs rather than in non-CACs 
(weak recommendation, very low certainty of evidence).
We cannot make a recommendation for or against 
regional triage by primary EMS transport of patients 
with OHCA to a CAC (bypass protocols) or secondary 
interfacility transfer to a CAC. The current evidence is 
inconclusive, and confidence in the effect estimates is 
currently too low to support an EIT and ALS Task Forces 
recommendation.
For patients with IHCA, we found no evidence to 
support an EIT and ALS Task Forces recommendation.
For the subgroup of patients with shockable or non-
shockable initial cardiac rhythm, the current evidence is 
inconclusive, and the confidence in the effect estimates 
is currently too low to support an EIT and ALS Task Forc-
es recommendation.
Justification and Evidence to Decision Framework 
Highlights
In making this recommendation, the EIT and ALS Task 
Forces concluded that the potential benefits in clinical 
outcomes outweighed the potential risks and logistical 
issues with implementation.
We specifically considered the consistency of im-
proved outcomes in patients treated at CACs across 
most studies, the desirability of patients receiving evi-
dence-based postresuscitation care, the evidence sup-
porting specialized care for other emergency conditions 
(eg, trauma, stroke, and ST-segment–elevation myocar-
dial infarction), the lack of evidence suggesting clini-
cal harm associated with longer transport times,213 the 
potential for referral bias (ie, transporting patients most 
likely to survive), and the implementation challenges of 
this recommendation.
Regionalized systems of care for cardiac arrest may 
not be feasible in all areas as a result of resource con-
straints, cost, and inherent regional differences in 
healthcare delivery. In making a weak recommendation 
in support of CACs, the task forces acknowledge the 
lack of high-level evidence.
EIT and ALS Task Forces Knowledge Gaps
Numerous knowledge gaps were identified in this SR. 
Key gaps include the following:
• There is no universal definition of a CAC.
• The precise aspects of CACs that improve outcomes 
have not been identified (eg, if there are specific bun-
dles of care that CACs offer that improve outcomes).
• The effect of delayed secondary interfacility trans-
fer to a CAC is unknown.
Table 16. Summary of Evidence on Outcomes Associated With Care in CACs
Outcomes (Importance)
 Studies  
(Participants), n
Certainty of the 
Evidence (GRADE) Odds Ratio (95% CI)
Anticipated Absolute Effects, n
Care at Other 
Hospital, n (%)
Risk Difference for 
Care at CAC
Survival to 30 d with favorable 
neurological outcome (critical)
2 studies188,189
(45 956)
Very low 2.92 (0.68–12.48) 359/25 617 (1.4) 26 more per 1000  
(4 fewer–137 more)
Survival to hospital discharge with 
favorable neurological outcome (critical)
2 studies194,195
(3673)
Very low 2.22 (1.74–2.84) 47/584 (8.0) 82 more per 1000 
(52–119 more)
Survival to 30 d (critical) 2 studies198,210
(2693)
Very low 2.14 (0.73–6.29) 123/1695 (7.3) 71 more per 1000  
(19 fewer–257 more)
Survival to hospital discharge (critical) 5 studies194,195,205–207
(11 662)
Very low 1.85 (1.46–2.34) 587/4117 (14.3) 93 more per 1000 
(53–138 more)
CAC indicates cardiac arrest centers; and GRADE, Grading of Recommendations, Assessment, Development, and Evaluation.
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• The potential benefit of CACs for IHCA and other 
subgroups (eg, cardiac pathogenesis, shockable 
rhythm) has not been reported.
FIRST AID TASK FORCE
Presyncope
Presyncope, or near-syncope, is the prodrome of synco-
pe and is characterized by light-headedness, nausea, di-
aphoresis, and a feeling of impending loss of conscious-
ness. A progression to syncope results in global cerebral 
hypoperfusion and transient loss of consciousness; loss 
of postural tone can result in physical injury in up to 
30% of patients.214 This review evaluated nonpharma-
cological first aid interventions that can be applied at 
the onset or immediately after the onset of presyncope 
symptoms. ILCOR commissioned an SR,12 and the task 
force studied all evidence cited in the SR and developed 
a draft CoSTR. The draft CoSTR was posted for public 
comment on the ILCOR website; the draft was viewed 
285 times during the comment period, and no com-
ments were posted.215 This document summarizes the 
final CoSTR for first aid treatment of presyncope.
Population, Intervention, Comparator, Outcome, 
Study Design, and Time Frame
Population: Adults and children with signs and symp-
toms of faintness or presyncope of suspected vasovagal 
or orthostatic origin
Intervention: Physical counterpressure maneuvers 
(PCMs), body positioning, hydration, or other
Comparison: Compared with no intervention or 1 
intervention compared with another
Outcomes:
• Abortion of syncope (termination of progression 
from presyncope to syncope; critical)
• Injuries or adverse events (critical)
• Symptom improvement (important)
• Change in heart rate (important)
• Change in systolic blood pressure (important)
• Change in diastolic blood pressure (important)
Study designs: RCTs and nonrandomized studies (non-
RCTs, interrupted time series, controlled before-and-
after studies, cohort studies) eligible for inclusion; case 
series and unpublished studies, published abstracts (eg, 
conference abstracts), and trial protocols excluded
Time frame: All years and all languages included 
(provided an English abstract was available)
PROSPERO registration: CRD42018107726
Consensus on Science
Studies Comparing Use of PCMs With a Control  
or No Use of PCMs
Eight studies were included in the SR, all evaluating the 
use of PCMs compared with no use of PCMs. PCMs 
involved the contraction of the large muscles of the 
legs, arms, or abdomen and included leg or arm tens-
ing, crossing, or squeezing; squatting; handgrip; and 
abdominal compression. Studies included 2 RCTs216,217 
and 6 observational studies,216,218–222 enrolling a total 
of 246 participants between 15 and 75 years of age 
with a history of vasovagal or orthostatic-related syn-
cope. Forms of PCMs evaluated included handgrip, 
squatting, leg crossing with tensing, and abdominal/
core muscle tensing. Evidence from the Brignole et al216 
RCT was downgraded to very low certainty as a result 
of risk of bias, inconsistency, indirectness, and impreci-
sion, whereas evidence from the Alizadeh et al217 RCT 
was downgraded to low certainty as a result of risk of 
bias, inconsistency, and indirectness. The observational 
studies all provide very-low-certainty evidence.216,218–222 
Table 17 gives a summary of studies.
Termination of Syncope. Use of handgrip PCMs in 
19 participants with vasovagal syncope and a positive 
tilt-table test increased the likelihood of terminating 
syncope in 1 RCT.216 However, no association was 
found between the termination of syncope and any 
form of PCM in 4 observational studies in laboratory 
settings with tilt-table testing.218–221 In 2 observational 
follow-up studies of 37 participants in settings of 
daily life,216,222 use of handgrip and arm-tensing PCMs 
was associated with termination of syncope in 99% 
of episodes involving subjects with known vasovagal 
origin presyncope. No adverse events or complications 
related to the use of handgrip PCMs were reported in 
any of these studies.
Alleviation of Symptoms of Presyncope. One RCT 
with 96 participants evaluated in daily life settings 
reported that the use of lower-body PCMs (squatting) 
or upper-body PCMs (handgrip) resulted in more alle-
viation of symptoms of presyncope than no PCMs.217 A 
second smaller RCT216 in a tilt-table test setting found 
more symptom improvement with the use of handgrip 
PCMs compared with no PCMs. One observational fol-
low-up study219 found symptom improvement in all 21 
participants with syncope of vasovagal origin in associa-
tion with the use of lower-body PCMs (squatting and 
abdominal tension).
Increase in Heart Rate and Blood Pressure. An 
increase in heart rate after the use of handgrip PCMs 
was reported in a single RCT,216 although 4 observa-
tional studies218–221 did not report consistent changes in 
heart rate. The same single RCT216 found improved sys-
tolic blood pressure with the use of handgrip PCMs, and 
2 pooled observational studies219,220 reported increased 
systolic and diastolic blood pressures associated with 
the use of lower-body PCMs.
Subgroup Analysis. A subgroup weighted meta-
analysis of 64 adults with vasovagal presyncope only 
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Table 17. Summary Data From Presyncope Studies
Outcomes Intervention: Comparison
Participants
(Studies), n RR (95% CI)
Certainty of
Evidence
(GRADE)
Risk With
Control/No PCM
Risk With
Intervention
(Risk Difference)
Prevention
of
syncope
Any PCM vs control (no use of 
PCM or standing only)
92 OH and VVS 
pathogenesis
(4 observational)218–221
1.31 (0.98– 1.75) Very low 594 per 1000 184 more per 1000
(12 fewer–445 more)
Risk difference, 0.19 
(0.01–0.37)
64 VVS pathogenesis
(3 observational)218–220
2.20 (0.96–5.05) Very low 277 per 1000 222 more per 1000 
(11 fewer–1000 
more)
Lower-body PCM vs control (no 
use of PCM or standing only)
36 VVS pathogenesis
(1 observational)220
2.20 (0.96–5.05) Very low  333 more per 1000 
(3–586 more)
Upper-body PCM vs
control (no use of PCM or 
standing only)
19 VVS pathogenesis
(1 RCT)216
1.80 (1.16–2.79) Very low 526 per 1000 421 more per 1000 
(84 –942 more)
14 VVS pathogenesis
(1 observational)218
29.00 (1.90–443.25) Very low   
37 VVS pathogenesis
(2 observational)216,222
99.4% of
episodes
(349/351)
(RR not estimable,
no comparisons)
Very low   
Lower-body PCM vs upper-
body PCM
27 VVS pathogenesis
(1 observational)221
7.00 (1.10–44.61) Very low  1000 more per 1000 
(88–1000)
Injuries or
adverse
events
Upper-body PCM vs control
(no use of PCM or standing 
only)
37 VVS pathogenesis
(2 observational)216,222
0/37 (0%) (RR
not estimable,
no comparisons)
Very low  0 fewer per 1000
(0–0 fewer)
Symptom
improvement
Any PCM vs control (no use of 
PCM or standing only)
21 VVS pathogenesis
(1 observational)219
20/20 (RR not
estimable; 1 patient 
lost
to follow-up)
Very low   
96 VVS pathogenesis
(1 RCT)217
1.57 (0.98–2.51) Very low 440 per 1000 251 more per 1000 
(26–409 more)
Lower-body PCM vs control (no 
use of PCM or standing only)
96 VVS pathogenesis
(1 RCT)217
1.66 (1.02–2.69) Very low  290 more per 1000 
(9–744 more)
Upper-body PCM vs
control (no use of PCM or 
standing only)
19 VVS pathogenesis
(1 RCT)216
6.00 (1.55–23.26) Low  526 more per 1000 
(58–1000 more)
96 VVS pathogenesis, 
follow-up phase
(1 RCT)217
1.47 (0.89–2.44) Very low  207 more per 1000 
(48 fewer–634 more)
Lower-body PCM vs upper-
body PCM
96 VVS pathogenesis
(1 RCT)217
0.89 (0.65–1.22) Very low  80 fewer per 1000 
(30 fewer–130 more)
Heart rate Upper-body vs control (no use 
of PCM or standing only)
19 VVS pathogenesis
(1 RCT)216
 Very low  MD, 8 bpm higher
(6.4–22.4 higher)
Lower-body PCM vs upper-
body PCM
27 VVS pathogenesis, 
handgrip vs
squatting
(1 observational)221
 Very low  MD, 0.8 bpm lower
(5.5 lower–3.9 
higher)
27 VVS pathogenesis, 
leg crossing vs
handgrip
(1 observational)221
 Very low  MD, 6.3 bpm higher
(3.0–9.5 higher)
Systolic
blood
pressure
Any PCM vs control (no use of 
PCM or standing only)
39 VVS pathogenesis
(2 observational)219,220
 Very low  MD, 21 mm Hg 
higher
(18.25–23.41 higher)
Lower-body PCM vs control
(no use of PCM or standing 
only)
18 VVS pathogenesis
(1 observational)220
 Very low  MD, 19 mm Hg 
higher
(16.31–21.69 higher)
Upper-body PCM vs control
(no use of PCM or standing 
only)
19 VVS pathogenesis
(1 RCT)216
 Low  MD, 32 mm Hg 
higher
(12.48–51.52 higher)
(Continued )
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from 3 observational studies219–221 failed to find an asso-
ciation between the use of PCMs and reduced likeli-
hood of progression from presyncope to syncope but 
did show an association with a greater likelihood of 
symptom improvement and an increase in heart rate 
and blood pressure.
Upper-Body Compared With Lower-Body PCMs. 
The use of upper-body PCMs compared with lower-
body PCMs was evaluated by 1 observational study221 
that reported a greater likelihood for termination of 
syncope and increase in heart rate and blood pres-
sure associated with the use of lower-body PCMs. 
Results from 1 RCT217 did not find greater improve-
ment in symptoms of presyncope with the use 
of lower-body PCMs compared with upper-body 
PCMs.
Additional Interventions for Presyncope. No stud-
ies were identified that evaluated the use of other 
interventions such as hydration or change of position 
applied at the onset of symptoms of presyncope.
Treatment Recommendations
We recommend the use of any type of PCM by individu-
als with acute symptoms of presyncope from vasovagal 
or orthostatic causes in the first aid setting (strong rec-
ommendation, low and very low certainty of evidence).
We suggest that lower-body PCMs such as leg cross-
ing and tensing or squatting are preferable to upper-
body and abdominal PCMs (weak recommendation, 
very low certainty of evidence).
Justification and Evidence to Decision  
Framework Highlights
Despite the mixed results and low- or very-low-cer-
tainty evidence identified in this review, using the Evi-
dence to Decision Framework215 and discussing all evi-
dence, the First Aid Task Force concluded that the use 
of PCMs for acute symptoms of presyncope warranted 
a strong recommendation because, together, the in-
cluded studies suggest that the use of PCMs results 
in better outcomes with no reported adverse events. 
In addition, PCM interventions are simple and inex-
pensive, and they may prevent the progression from 
Systolic
blood
pressure 
Continued
Lower-body PCM vs upper-
body PCM
27 VVS pathogenesis, 
squatting vs
handgrip
(1 observational)221
 Very low  MD, 12.5 mm Hg 
higher
(5.69–19.31 higher)
27 VVS pathogenesis, 
leg crossing
vs handgrip
(1 observational)221
 Very low  MD, 11.6 mm Hg 
higher
(4.3–18.8 higher)
Lower-body PCM vs abdominal 
PCM
9 neurogenic OH 
pathogenesis
(1 observational)223
 Very low  MD, 36.5 higher
(15.00–57.99 higher)
Lower-body PCM vs neck PCM 9 neurogenic OH 
pathogenesis
(1 observational)223
 Very low  MD, 28.2 higher
(10.79–45.61 higher)
Diastolic
blood
pressure
Any PCM vs control (no use of 
PCM or standing only)
39 VVS pathogenesis
(2 observational)219,220
 Very low  MD, 11 mm Hg 
higher
(9.39–13.10 higher)
Lower-body PCM vs control (no 
use of PCM or standing only)
18 VVS pathogenesis
(1 observational)220
 Very low  MD, 10 mm Hg 
higher
(8.04–11.96 higher)
Upper-body PCM vs control (no 
use of PCM or standing only)
19 VVS pathogenesis
(1 RCT)221
 Very low  MD, 20 mm Hg 
higher
(5.95–34.05 higher)
Lower-body PCM vs
upper-body PCM
27 VVS pathogenesis
(1 observational)221
 Very low  MD, 3.3 mm Hg 
higher
(2.28 lower–8.88 
higher)
27 VVS pathogenesis
(1 observational)221
 Very low  MD, 1.3 mm Hg 
higher
(6.88 lower–4.28 
mm Hg higher)
GRADE indicates Grading of Recommendations, Assessment, Development, and Evaluation; MD, mean difference; OH, orthostatic hypotension; PCM, physical 
counterpressure maneuvers; RCT, randomized controlled trial; RR, relative risk; and VVS, vasovagal syncope.
Table 17. Continued
Outcomes Intervention: Comparison
Participants
(Studies), n RR (95% CI)
Certainty of
Evidence
(GRADE)
Risk With
Control/No PCM
Risk With
Intervention
(Risk Difference)
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presyncope to syncope and risks of subsequent injury. 
Successful treatment of presyncope may improve the 
QOL for those with recurrent vasovagal or orthostatic 
syncope, and it may ultimately decrease associated 
healthcare costs. Included studies demonstrated that 
training of participants in the use of PCMs at symp-
tom onset was feasible and similar to a first aid situa-
tion, making it likely that first aid providers can also be 
trained in their use.
Although there is little evidence comparing different 
methods of PCMs, observational studies suggested that 
the use of lower-body PCMs may have an advantage 
over upper-body PCMs for the outcome of terminating 
presyncope. Despite this, the task force recognizes the 
practicality of the use of a variety of PCM techniques 
for first aid, particularly when PCM interventions may 
be limited by patient location and position.
Knowledge Gaps
The task force identified several knowledge gaps re-
quiring further investigation:
• Validity of conventional first aid recommendation 
to place a person with symptoms of presyncope 
into a sitting or supine position with or without a 
combination of PCMs
• Effectiveness of additional interventions such as 
hydration
• Clinical outcomes related to the use of PCMs and 
possible variation based on age, sex, and cause of 
presyncope
• Ability of first aid providers to recognize vasovagal 
and orthostatic presyncope and to assess clinical 
outcomes after instruction in and use of PCMs
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